

Table 10.6.A

EXPLANTATION (REMOVAL) FOR ANY REASON REGARDLESS OF REPLACEMENT: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Age (years)	1.001	0.9787
Race		0.3361
Caucasian	1.000 (reference)	
Other	0.366	
Smoking Status		0.8217
No	1.000 (reference)	
Yes	0.885	
Surgical Approach		0.0427
Inframammary	1.000 (reference)	
Periareolar	0.735	
Transaxillary	2.501	
Mastectomy Scar	N/A	
Other/Mixed	8.596	
Surgical Placement		0.9935
Submuscular/Subpectoral	1.000 (reference)	
Subglandular	0.995	
Other/Mixed	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10.A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.6.A

EXPLANTATION (REMOVAL) FOR ANY REASON REGARDLESS OF REPLACEMENT: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Incision Size (cm)	0.965	0.8612
Surface Type		
Smooth	1.000 (reference)	
Textured	2.194	
Mixed	N/A	
Prior Tissue Expander*		
Yes		
No	N/A	
Irrigation Solutions Used in Pocket		0.8068
Saline Only	1.000 (reference)	
Steroid Only	0.000	
Antibiotic Only	1.646	
Drug Only	9.011	
Other	4.456	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.6.A

EXPLANTATION (REMOVAL) FOR ANY REASON REGARDLESS OF REPLACEMENT: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Implant Size		0.3472
<=349 cc	N/A	
350-399 cc	2.147	
400-499 cc	1.808	
500-599 cc	6.104	
>=600 cc	0.000	
Site		0.9855
Pooled Site	1.000 (reference)	
Site 1	1.326	
Site 2	0.449	
Site 3	0.493	
Site 4	0.482	
Site 5	0.000	
Site 7	1.644	
Site 8	0.000	
Site 10	0.241	
Site 12	0.000	
Site 13	0.471	
Site 15	0.902	
Site 18	0.395	
Site 19	N/A	
Site 23	1.318	
Site 30	N/A	
Site 33	N/A	
Site 48	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08.58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following. asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 10.7.A

EXPLANATION (REMOVAL) FOR ANY REASON WITH REPLACEMENT. COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Age (years)	1.015	0.6722
Race		0.6875
Caucasian	1.000 (reference)	
Other	0.649	
Smoking Status		0.6368
No	1.000 (reference)	
Yes	0.719	
Surgical Approach		0.0910
Inframammary	1.000 (reference)	
Periareolar	0.794	
Transaxillary	2.647	
Mastectomy Scar	N/A	
Other/Mixed	11.685	
Surgical Placement		0.7280
Submuscular/Subpectoral	1.000 (reference)	
Subglandular	0.779	
Other/Mixed	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.7.A

EXPLANATION (REMOVAL) FOR ANY REASON WITH REPLACEMENT: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Incision Size (cm)	0.882	0.6638
Surface Type		
Smooth	1.000 (reference)	
Textured	1.425	
Mixed	N/A	
Prior Tissue Expander*		
Yes		
No	N/A	
Irrigation Solutions Used in Pocket		0.9612
Saline Only	1.000 (reference)	
Steroid Only	0.000	
Antibiotic Only	0.807	
Drug Only	1.079	
Other	2.117	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 10.7.A

EXPLANATION (REMOVAL) FOR ANY REASON WITH REPLACEMENT: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Implant Size		0.5319
<=349 cc	N/A	
350-399 cc	3.044	
400-499 cc	1.984	
500-599 cc	5.966	
>=600 cc	0.000	
Site		0.9988
Pooled Site	1.000 (reference)	
Site 1	0.788	
Site 2	0.333	
Site 3	0.654	
Site 4	1.228	
Site 5	0.000	
Site 7	1.716	
Site 8	0.000	
Site 10	0.290	
Site 12	0.000	
Site 13	0.577	
Site 15	0.909	
Site 18	0.000	
Site 19	N/A	
Site 23	0.295	
Site 30	N/A	
Site 33	N/A	
Site 48	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.8.A

EXPLANTATION (REMOVAL) FOR ANY REASON WITHOUT REPLACEMENT: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Age (years)	0.970	0.4646
Race		0.9959
Caucasian	1.000 (reference)	
Other	0.000	
Smoking Status		0.8756
No	1.000 (reference)	
Yes	0.856	
Surgical Approach		0.6603
Inframammary	1.000 (reference)	
Periareolar	0.641	
Transaxillary	1.468	
Mastectomy Scar	N/A	
Other/Mixed	6.307	
Surgical Placement		0.6064
Submuscular/Subpectoral	1.000 (reference)	
Subglandular	1.896	
Other/Mixed	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.8.A

EXPLANATION (REMOVAL) FOR ANY REASON WITHOUT REPLACEMENT. COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Incision Size (cm)	1.092	0.7388
Surface Type		
Smooth	1.000 (reference)	
Textured	2.582	
Mixed	N/A	
Prior Tissue Expander*		
Yes		
No	N/A	
Irrigation Solutions Used in Pocket		0.9889
Saline Only	1.000 (reference)	
Steroid Only	>100	
Antibiotic Only	>100	
Drug Only	>100	
Other	>100	

Program Name. Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.8.A

EXPLANTATION (REMOVAL) FOR ANY REASON WITHOUT REPLACEMENT: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Implant Size		0.6721
<=349 cc	N/A	
350-399 cc	1.957	
400-499 cc	1.556	
500-599 cc	6.895	
>=600 cc	0.353	
Site		0.9995
Pooled Site	1.000 (reference)	
Site 1	2.208	
Site 2	0.734	
Site 3	0.000	
Site 4	0.000	
Site 5	0.000	
Site 7	1.357	
Site 8	0.125	
Site 10	0.000	
Site 12	0.000	
Site 13	0.000	
Site 15	0.753	
Site 18	3.130	
Site 19	N/A	
Site 23	5.060	
Site 30	N/A	
Site 33	N/A	
Site 48	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.9.A

ANY REOPERATION TO THE BREAST OR SURROUNDING AREAS: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Age (years)	1.009	0.5623
Race		0.5698
Caucasian	1.000 (reference)	
Other	0.800	
Smoking Status		0.3523
No	1.000 (reference)	
Yes	0.736	
Surgical Approach		0.0058
Inframammary	1.000 (reference)	
Periareolar	0.622	
Transaxillary	1.260	
Mastectomy Scar	N/A	
Other/Mixed	5.142	
Surgical Placement		0.6281
Submuscular/Subpectoral	1.000 (reference)	
Subglandular	1.158	
Other/Mixed	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10.A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following. asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 10.9.A

ANY REOPERATION TO THE BREAST OR SURROUNDING AREAS: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Incision Size (cm)	0.954	0.5953
Surface Type		
Smooth	1.000 (reference)	
Textured	0.874	
Mixed	N/A	
Prior Tissue Expander*		
Yes		
No	N/A	
Irrigation Solutions Used in Pocket		0.0996
Saline Only	1.000 (reference)	
Steroid Only	0.000	
Antibiotic Only	0.536	
Drug Only	7.861	
Other	2.840	

Program Name: O:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 10.9.A

ANY REOPERATION TO THE BREAST OR SURROUNDING AREAS: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Implant Size		0.8376
<=349 cc	N/A	
350-399 cc	0.803	
400-499 cc	0.753	
500-599 cc	1.267	
>=600 cc	0.000	
Site		0.4277
Pooled Site	1.000 (reference)	
Site 1	1.783	
Site 2	0.446	
Site 3	0.471	
Site 4	0.959	
Site 5	1.788	
Site 7	0.282	
Site 8	0.296	
Site 10	0.270	
Site 12	0.121	
Site 13	0.253	
Site 15	0.528	
Site 18	0.164	
Site 19	N/A	
Site 23	0.289	
Site 30	N/A	
Site 33	N/A	
Site 48	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 10.10.A

ANY COMPLICATION: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Age (years)	1.001	0.8962
Race		0.0956
Caucasian	1.000 (reference)	
Other	1.445	
Smoking Status		0.4934
No	1.000 (reference)	
Yes	0.871	
Surgical Approach		0.0936
Inframammary	1.000 (reference)	
Periareolar	0.669	
Transaxillary	1.012	
Mastectomy Scar	N/A	
Other/Mixed	2.457	
Surgical Placement		0.7307
Submuscular/Subpectoral	1.000 (reference)	
Subglandular	1.071	
Other/Mixed	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note. Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10 10.A

ANY COMPLICATION: COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Incision Size (cm)	1.012	0.8480
Surface Type		
Smooth	1.000 (reference)	
Textured	1.518	
Mixed	N/A	
Prior Tissue Expander*		
Yes		
No	N/A	
Irrigation Solutions Used in Pocket		0.8992
Saline Only	1.000 (reference)	
Steroid Only	2.557	
Antibiotic Only	1.274	
Drug Only	1.194	
Other	1.461	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08:58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Table 10.10.A

ANY COMPLICATION. COX REGRESSION

Explanatory Variables	Augmentation Patients	
	Estimated Hazard Ratio	p-value
Implant Size		0.5244
<=349 cc	N/A	
350-399 cc	0.767	
400-499 cc	0.821	
500-599 cc	1.302	
>=600 cc	0.759	
Site		0.9269
Pooled Site	1.000 (reference)	
Site 1	1.136	
Site 2	0.910	
Site 3	0.698	
Site 4	0.759	
Site 5	1.101	
Site 7	0.576	
Site 8	1.458	
Site 10	0.680	
Site 12	0.492	
Site 13	1.182	
Site 15	0.894	
Site 18	0.831	
Site 19	N/A	
Site 23	0.700	
Site 30	N/A	
Site 33	N/A	
Site 48	N/A	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T10_A.SAS

Creation Date, Time: 24AUG04 08.58

* Only Included in model for Reconstruction Patients.

Note: Excludes planned second stage surgeries and mild occurrences of the following: asymmetry, breast pain not associated with any other complication, calcification, position change, nipple-unacceptably low sensitivity, breast-unacceptably low/high sensitivity, nipple complications, and wrinkling.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.1

INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
AUGMENTATION PATIENTS

Type of Diagnoses	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Diagnosis of Rheumatic Disease	0 (0)	3 (0.5)		3 (0.5)
INFLAMMATORY ARTHRITIS:				
RHEUMATOID ARTHRITIS	0 (0)	1 (0.2)		1 (0.2)
OTHERS:				
HASHIMOTO'S THYROIDITIS	0 (0)	1 (0.2)		1 (0.2)
HYPOTHYROIDISM	0 (0)	1 (0.2)		1 (0.2)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.1

INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
RECONSTRUCTION PATIENTS

Type of Diagnoses	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Diagnosis of Rheumatic Disease	1 (0.4)	0 (0)		1 (0.4)
NON-INFLAMMATORY RHEUMATIC CONDITIONS: FIBROMYALGIA	1 (0.4)	0 (0)		1 (0.4)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.1

INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
REVISION PATIENTS

Type of Diagnoses	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Diagnosis of Rheumatic Disease	2 (1.0)	0 (0)		2 (1.0)
NON-INFLAMMATORY RHEUMATIC CONDITIONS:				
FIBROMYALGIA	1 (0.5)	0 (0)		1 (0.5)
OTHERS:				
PYODERMA GANGRENOSUM	1 (0.5)	0 (0)		1 (0.5)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.1

INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
OVERALL PATIENTS

Type of Diagnoses	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Diagnosis of Rheumatic Disease	3 (0.3)	3 (0.3)		6 (0.6)
INFLAMMATORY ARTHRITIS:				
RHEUMATOID ARTHRITIS	0 (0)	1 (0.1)		1 (0.1)
NON-INFLAMMATORY RHEUMATIC CONDITIONS:				
FIBROMYALGIA	2 (0.2)	0 (0)		2 (0.2)
OTHERS:				
HASHIMOTO'S THYROIDITIS	0 (0)	1 (0.1)		1 (0.1)
HYPOTHYROIDISM	0 (0)	1 (0.1)		1 (0.1)
PYODERMA GANGRENOSUM	1 (0.1)	0 (0)		1 (0.1)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.2

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYSTEM CATEGORY
AUGMENTATION PATIENTS

Rheumatologic System Category	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic System Category	21 (3.8)	25 (4.5)	17 (3.1)	51 (9.3)
Skin and Appendages	2 (0.4)	4 (0.7)	4 (0.7)	10 (1.8)
Muscle	6 (1.1)	7 (1.3)	5 (0.9)	18 (3.3)
Joint	3 (0.5)	8 (1.5)	3 (0.5)	14 (2.5)
CNS	7 (1.3)	8 (1.5)	5 (0.9)	20 (3.6)
Gastrointestinal	1 (0.2)	2 (0.4)	1 (0.2)	4 (0.7)
Body as a Whole	4 (0.7)	10 (1.8)	4 (0.7)	18 (3.3)
Metabolic and Nutritional	0 (0)	1 (0.2)	1 (0.2)	2 (0.4)
Hearing and Vestibular	1 (0.2)	5 (0.9)	1 (0.2)	7 (1.3)
Respiratory	0 (0)	2 (0.4)	0 (0)	2 (0.4)
Platelet, Bleeding, Clotting Disorder	1 (0.2)	0 (0)	1 (0.2)	2 (0.4)
Cardiovascular	1 (0.2)	0 (0)	0 (0)	1 (0.2)
Vision	2 (0.4)	2 (0.4)	0 (0)	4 (0.7)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.2

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYSTEM CATEGORY
RECONSTRUCTION PATIENTS

Rheumatologic System Category	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic System Category	20 (8.0)	18 (7.2)	5 (2.0)	40 (15.9)
Skin and Appendages	1 (0.4)	0 (0)	1 (0.4)	2 (0.8)
Muscle	6 (2.4)	6 (2.4)	2 (0.8)	14 (5.6)
Joint	9 (3.6)	6 (2.4)	0 (0)	15 (6.0)
CNS	1 (0.4)	2 (0.8)	1 (0.4)	4 (1.6)
Gastrointestinal	0 (0)	0 (0)	1 (0.4)	1 (0.4)
Body as a Whole	6 (2.4)	9 (3.6)	2 (0.8)	17 (6.8)
Metabolic and Nutritional	1 (0.4)	0 (0)	0 (0)	1 (0.4)
Hearing and Vestibular	0 (0)	1 (0.4)	0 (0)	1 (0.4)
Platelet, Bleeding, Clotting Disorder	0 (0)	1 (0.4)	0 (0)	1 (0.4)
Vision	1 (0.4)	1 (0.4)	0 (0)	2 (0.8)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.2

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYSTEM CATEGORY
REVISION PATIENTS

Rheumatologic System Category	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic System Category	17 (8.3)	17 (8.3)	8 (3.9)	36 (17.6)
Skin and Appendages	3 (1.5)	2 (1.0)	3 (1.5)	8 (3.9)
Muscle	5 (2.4)	7 (3.4)	3 (1.5)	15 (7.3)
Joint	4 (2.0)	6 (2.9)	0 (0)	10 (4.9)
CNS	5 (2.4)	8 (3.9)	1 (0.5)	14 (6.8)
Gastrointestinal	2 (1.0)	3 (1.5)	0 (0)	5 (2.4)
Body as a Whole	11 (5.4)	11 (5.4)	1 (0.5)	23 (11.2)
Metabolic and Nutritional	1 (0.5)	2 (1.0)	0 (0)	3 (1.5)
Hearing and Vestibular	3 (1.5)	1 (0.5)	1 (0.5)	5 (2.4)
Respiratory	0 (0)	1 (0.5)	0 (0)	1 (0.5)
Platelet, Bleeding, Clotting Disorder	1 (0.5)	2 (1.0)	1 (0.5)	4 (2.0)
Vision	0 (0)	2 (1.0)	0 (0)	2 (1.0)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.2

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYSTEM CATEGORY
OVERALL PATIENTS

Rheumatologic System Category	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic System Category	58 (5.8)	60 (6.0)	30 (3.0)	127 (12.6)
Skin and Appendages	6 (0.6)	6 (0.6)	8 (0.8)	20 (2.0)
Muscle	17 (1.7)	20 (2.0)	10 (1.0)	47 (4.7)
Joint	16 (1.6)	20 (2.0)	3 (0.3)	39 (3.9)
CNS	13 (1.3)	18 (1.8)	7 (0.7)	38 (3.8)
Gastrointestinal	3 (0.3)	5 (0.5)	2 (0.2)	10 (1.0)
Body as a Whole	21 (2.1)	30 (3.0)	7 (0.7)	58 (5.8)
Metabolic and Nutritional	2 (0.2)	3 (0.3)	1 (0.1)	6 (0.6)
Hearing and Vestibular	4 (0.4)	7 (0.7)	2 (0.2)	13 (1.3)
Respiratory	0 (0)	3 (0.3)	0 (0)	3 (0.3)
Platelet, Bleeding, Clotting Disorder	2 (0.2)	3 (0.3)	2 (0.2)	7 (0.7)
Cardiovascular	1 (0.1)	0 (0)	0 (0)	1 (0.1)
Vision	3 (0.3)	5 (0.5)	0 (0)	8 (0.8)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
AUGMENTATION PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Symptom Type	21 (3.8)	25 (4.5)	17 (3.1)	51 (9.3)
LOSS OF WEIGHT WITHOUT DIETING	0 (0)	1 (0.2)	1 (0.2)	2 (0.4)
FATIGUE	1 (0.2)	6 (1.1)	2 (0.4)	9 (1.6)
INSOMNIA	2 (0.4)	5 (0.9)	1 (0.2)	8 (1.5)
WEAKNESS	1 (0.2)	2 (0.4)	0 (0)	3 (0.5)
EXHAUSTION	1 (0.2)	3 (0.5)	1 (0.2)	5 (0.9)
JOINT SWELLING	1 (0.2)	3 (0.5)	0 (0)	4 (0.7)
HEEL PAIN	1 (0.2)	2 (0.4)	2 (0.4)	5 (0.9)
FREQUENT MUSCLE CRAMPS	1 (0.2)	3 (0.5)	1 (0.2)	5 (0.9)
NUMBNESS OF FEET	1 (0.2)	3 (0.5)	1 (0.2)	5 (0.9)
RINGING IN EARS	1 (0.2)	5 (0.9)	1 (0.2)	7 (1.3)
PAIN/GRITTIENESS IN EYES	2 (0.4)	1 (0.2)	0 (0)	3 (0.5)
DRYNESS OF EYES/NOSE	0 (0)	1 (0.2)	0 (0)	1 (0.2)
NECK PAIN/STIFFNESS	3 (0.5)	3 (0.5)	3 (0.5)	9 (1.6)
HEART MURMURS	1 (0.2)	0 (0)	0 (0)	1 (0.2)
LOSS OF APPETITE	0 (0)	1 (0.2)	0 (0)	1 (0.2)
NIGHT SWEATS	2 (0.4)	3 (0.5)	2 (0.4)	7 (1.3)
GENERALIZED ACHING	0 (0)	4 (0.7)	1 (0.2)	5 (0.9)
JOINT PAIN	2 (0.4)	7 (1.3)	3 (0.5)	12 (2.2)
FREQUENT MUSCLE PAIN	0 (0)	2 (0.4)	0 (0)	2 (0.4)
NUMBNESS OF HANDS	5 (0.9)	5 (0.9)	3 (0.5)	13 (2.4)
REDNESS OF EYES	0 (0)	1 (0.2)	1 (0.2)	2 (0.4)
DRYNESS OF MOUTH	0 (0)	1 (0.2)	0 (0)	1 (0.2)
BACK PAIN/STIFFNESS	2 (0.4)	4 (0.7)	0 (0)	6 (1.1)

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_3.SAS

Creation Date, Time: 27JUL04 11:47

(a) Includes only rheumatologic physical findings that had an onset date during the time period of interest.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
AUGMENTATION PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
SEVERE CHEST PAINS	1 (0.2)	1 (0.2)	0 (0)	2 (0.4)
CHRONIC COUGH	0 (0)	2 (0.4)	0 (0)	2 (0.4)
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	1 (0.2)	1 (0.2)	1 (0.2)	3 (0.5)
SEVERE RASHES	1 (0.2)	2 (0.4)	0 (0)	3 (0.5)
SEVERE DRYNESS OF SKIN	1 (0.2)	0 (0)	2 (0.4)	3 (0.5)
TENDER LUMPS/BUMPS	0 (0)	1 (0.2)	0 (0)	1 (0.2)
FREQUENT HIVES	0 (0)	1 (0.2)	0 (0)	1 (0.2)
UNUSUAL HAIR LOSS	0 (0)	1 (0.2)	2 (0.4)	3 (0.5)
SEVERE BRUISING WITH LITTLE OR NO INJURY	1 (0.2)	0 (0)	1 (0.2)	2 (0.4)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Symptom Type	20 (8.0)	19 (7.6)	5 (2.0)	40 (15.9)
LOSS OF WEIGHT WITHOUT DIETING	1 (0.4)	0 (0)	0 (0)	1 (0.4)
FATIGUE	2 (0.8)	4 (1.6)	1 (0.4)	7 (2.8)
INSOMNIA	1 (0.4)	2 (0.8)	1 (0.4)	4 (1.6)
WEAKNESS	0 (0)	0 (0)	1 (0.4)	1 (0.4)
EXHAUSTION	0 (0)	2 (0.8)	0 (0)	2 (0.8)
JOINT SWELLING	2 (0.8)	3 (1.2)	0 (0)	5 (2.0)
HEEL PAIN	0 (0)	1 (0.4)	1 (0.4)	2 (0.8)
FREQUENT MUSCLE CRAMPS	3 (1.2)	5 (2.0)	0 (0)	8 (3.2)
RINGING IN EARS	0 (0)	1 (0.4)	0 (0)	1 (0.4)
PAIN/GRITTIENESS IN EYES	1 (0.4)	1 (0.4)	0 (0)	2 (0.8)
DRYNESS OF EYES/NOSE	1 (0.4)	1 (0.4)	0 (0)	2 (0.8)
NECK PAIN/STIFFNESS	0 (0)	2 (0.8)	2 (0.8)	4 (1.6)
NIGHT SWEATS	2 (0.8)	2 (0.8)	1 (0.4)	5 (2.0)
GENERALIZED ACHING	1 (0.4)	2 (0.8)	0 (0)	3 (1.2)
LOSS OF HEIGHT	2 (0.8)	2 (0.8)	0 (0)	4 (1.6)
JOINT PAIN	9 (3.6)	5 (2.0)	0 (0)	14 (5.6)
FREQUENT MUSCLE PAIN	2 (0.8)	1 (0.4)	0 (0)	3 (1.2)
JAW PAIN	0 (0)	0 (0)	1 (0.4)	1 (0.4)
BACK PAIN/STIFFNESS	2 (0.8)	1 (0.4)	0 (0)	3 (1.2)
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	0 (0)	0 (0)	1 (0.4)	1 (0.4)
TENDER LUMPS/BUMPS	0 (0)	1 (0.4)	0 (0)	1 (0.4)
UNUSUAL HAIR LOSS	1 (0.4)	0 (0)	1 (0.4)	2 (0.8)
TENDERNESS OF SCALP	1 (0.4)	0 (0)	0 (0)	1 (0.4)

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11 3.SAS

Creation Date, Time: 27JUL04 11:47

(a) Includes only rheumatologic physical findings that had an onset date during the time period of interest.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
SEVERE BRUISING WITH LITTLE OR NO INJURY	0 (0)	1 (0.4)	0 (0)	1 (0.4)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
REVISION PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Symptom Type	17 (8.3)	18 (8.8)	8 (3.9)	36 (17.6)
LOSS OF WEIGHT WITHOUT DIETING	1 (0.5)	2 (1.0)	0 (0)	3 (1.5)
FATIGUE	5 (2.4)	4 (2.0)	2 (1.0)	11 (5.4)
INSOMNIA	2 (1.0)	3 (1.5)	0 (0)	5 (2.4)
WEAKNESS	1 (0.5)	3 (1.5)	1 (0.5)	5 (2.4)
EXHAUSTION	1 (0.5)	4 (2.0)	1 (0.5)	6 (2.9)
JOINT SWELLING	0 (0)	3 (1.5)	1 (0.5)	4 (2.0)
HEEL PAIN	2 (1.0)	0 (0)	0 (0)	2 (1.0)
FREQUENT MUSCLE CRAMPS	1 (0.5)	3 (1.5)	1 (0.5)	5 (2.4)
NUMBNESS OF FEET	2 (1.0)	1 (0.5)	1 (0.5)	4 (2.0)
RINGING IN EARS	3 (1.5)	1 (0.5)	1 (0.5)	5 (2.4)
DRYNESS OF EYES/NOSE	1 (0.5)	1 (0.5)	0 (0)	2 (1.0)
PAIN ON SWALLOWING OR CHEWING	0 (0)	2 (1.0)	0 (0)	2 (1.0)
NECK PAIN/STIFFNESS	3 (1.5)	1 (0.5)	0 (0)	4 (2.0)
PAIN ON BREATHING	0 (0)	1 (0.5)	0 (0)	1 (0.5)
LOSS OF APPETITE	0 (0)	2 (1.0)	0 (0)	2 (1.0)
NIGHT SWEATS	3 (1.5)	1 (0.5)	0 (0)	4 (2.0)
GENERALIZED ACHING	2 (1.0)	4 (2.0)	1 (0.5)	7 (3.4)
LOSS OF HEIGHT	0 (0)	1 (0.5)	0 (0)	1 (0.5)
JOINT PAIN	4 (2.0)	6 (2.9)	0 (0)	10 (4.9)
FREQUENT MUSCLE PAIN	2 (1.0)	0 (0)	0 (0)	2 (1.0)
NUMBNESS OF HANDS	1 (0.5)	6 (2.9)	1 (0.5)	8 (3.9)
JAW PAIN	1 (0.5)	0 (0)	0 (0)	1 (0.5)
REDNESS OF EYES	0 (0)	2 (1.0)	0 (0)	2 (1.0)

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_3.SAS

Creation Date, Time: 27JUL04 11:47

(a) Includes only rheumatologic physical findings that had an onset date during the time period of interest.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
REVISION PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
DRYNESS OF MOUTH	1 (0.5)	1 (0.5)	0 (0)	2 (1.0)
BACK PAIN/STIFFNESS	2 (1.0)	4 (2.0)	2 (1.0)	8 (3.9)
DIFFICULTY SWALLOWING	0 (0)	2 (1.0)	0 (0)	2 (1.0)
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	2 (1.0)	2 (1.0)	0 (0)	4 (2.0)
SEVERE DRYNESS OF SKIN	1 (0.5)	2 (1.0)	2 (1.0)	5 (2.4)
TENDER LUMPS/BUMPS	2 (1.0)	2 (1.0)	1 (0.5)	5 (2.4)
EXCESSIVE SENSITIVITY TO SUN	1 (0.5)	0 (0)	0 (0)	1 (0.5)
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	1 (0.5)	1 (0.5)	0 (0)	2 (1.0)
FREQUENT HIVES	1 (0.5)	0 (0)	0 (0)	1 (0.5)
UNUSUAL HAIR LOSS	1 (0.5)	1 (0.5)	1 (0.5)	3 (1.5)
TENDERNESS OF SCALP	1 (0.5)	0 (0)	0 (0)	1 (0.5)
SEVERE BRUISING WITH LITTLE OR NO INJURY	1 (0.5)	2 (1.0)	1 (0.5)	4 (2.0)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
OVERALL PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Symptom Type	58 (5.8)	62 (6.2)	30 (3.0)	127 (12.6)
LOSS OF WEIGHT WITHOUT DIETING	2 (0.2)	3 (0.3)	1 (0.1)	6 (0.6)
FATIGUE	8 (0.8)	14 (1.4)	5 (0.5)	27 (2.7)
INSOMNIA	5 (0.5)	10 (1.0)	2 (0.2)	17 (1.7)
WEAKNESS	2 (0.2)	5 (0.5)	2 (0.2)	9 (0.9)
EXHAUSTION	2 (0.2)	9 (0.9)	2 (0.2)	13 (1.3)
JOINT SWELLING	3 (0.3)	9 (0.9)	1 (0.1)	13 (1.3)
HEEL PAIN	3 (0.3)	3 (0.3)	3 (0.3)	9 (0.9)
FREQUENT MUSCLE CRAMPS	5 (0.5)	11 (1.1)	2 (0.2)	18 (1.8)
NUMBNESS OF FEET	3 (0.3)	4 (0.4)	2 (0.2)	9 (0.9)
RINGING IN EARS	4 (0.4)	7 (0.7)	2 (0.2)	13 (1.3)
PAIN/GRITTIENESS IN EYES	3 (0.3)	2 (0.2)	0 (0)	5 (0.5)
DRYNESS OF EYES/NOSE	2 (0.2)	3 (0.3)	0 (0)	5 (0.5)
PAIN ON SWALLOWING OR CHEWING	0 (0)	2 (0.2)	0 (0)	2 (0.2)
NECK PAIN/STIFFNESS	6 (0.6)	6 (0.6)	5 (0.5)	17 (1.7)
PAIN ON BREATHING	0 (0)	1 (0.1)	0 (0)	1 (0.1)
HEART MURMURS	1 (0.1)	0 (0)	0 (0)	1 (0.1)
LOSS OF APPETITE	0 (0)	3 (0.3)	0 (0)	3 (0.3)
NIGHT SWEATS	7 (0.7)	6 (0.6)	3 (0.3)	16 (1.6)
GENERALIZED ACHING	3 (0.3)	10 (1.0)	2 (0.2)	15 (1.5)
LOSS OF HEIGHT	2 (0.2)	3 (0.3)	0 (0)	5 (0.5)
JOINT PAIN	15 (1.5)	18 (1.8)	3 (0.3)	36 (3.6)
FREQUENT MUSCLE PAIN	4 (0.4)	3 (0.3)	0 (0)	7 (0.7)
NUMBNESS OF HANDS	6 (0.6)	11 (1.1)	4 (0.4)	21 (2.1)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.3

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOM BY SYMPTOM TYPE
OVERALL PATIENTS

Rheumatologic Symptom Type	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
JAW PAIN	1 (0.1)	0 (0)	1 (0.1)	2 (0.2)
REDNESS OF EYES	0 (0)	3 (0.3)	1 (0.1)	4 (0.4)
DRYNESS OF MOUTH	1 (0.1)	2 (0.2)	0 (0)	3 (0.3)
BACK PAIN/STIFFNESS	6 (0.6)	9 (0.9)	2 (0.2)	17 (1.7)
SEVERE CHEST PAINS	1 (0.1)	1 (0.1)	0 (0)	2 (0.2)
CHRONIC COUGH	0 (0)	2 (0.2)	0 (0)	2 (0.2)
DIFFICULTY SWALLOWING	0 (0)	2 (0.2)	0 (0)	2 (0.2)
FREQUENT,SEVERE DIARRHEA/CONSTIPATION	3 (0.3)	3 (0.3)	2 (0.2)	8 (0.8)
SEVERE RASHES	1 (0.1)	2 (0.2)	0 (0)	3 (0.3)
SEVERE DRYNESS OF SKIN	2 (0.2)	2 (0.2)	4 (0.4)	8 (0.8)
TENDER LUMPS/BUMPS	2 (0.2)	4 (0.4)	1 (0.1)	7 (0.7)
EXCESSIVE SENSITIVITY TO SUN	1 (0.1)	0 (0)	0 (0)	1 (0.1)
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	1 (0.1)	1 (0.1)	0 (0)	2 (0.2)
FREQUENT HIVES	1 (0.1)	1 (0.1)	0 (0)	2 (0.2)
UNUSUAL HAIR LOSS	2 (0.2)	2 (0.2)	4 (0.4)	8 (0.8)
TENDERNESS OF SCALP	2 (0.2)	0 (0)	0 (0)	2 (0.2)
SEVERE BRUISING WITH LITTLE OR NO INJURY	2 (0.2)	3 (0.3)	2 (0.2)	7 (0.7)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.4

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
AUGMENTATION PATIENTS

Rheumatologic Physical Finding	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Physical Finding	5 (0.9)	7 (1.3)	6 (1.1)	16 (2.9)
WEAK HEADLIFT	1 (0.2)	0 (0)	0 (0)	1 (0.2)
WRIST SWELLING	1 (0.2)	0 (0)	0 (0)	1 (0.2)
DIGITS SWELLING	2 (0.4)	1 (0.2)	1 (0.2)	4 (0.7)
KNEES SWELLING	1 (0.2)	0 (0)	1 (0.2)	2 (0.4)
ANKLES SWELLING	0 (0)	1 (0.2)	0 (0)	1 (0.2)
JOINT TENDERNESS	1 (0.2)	3 (0.5)	3 (0.5)	7 (1.3)
HAIR LOSS	0 (0)	0 (0)	1 (0.2)	1 (0.2)
SWOLLEN DIGITS	0 (0)	1 (0.2)	0 (0)	1 (0.2)
PAINLESS EYE REDNESS	0 (0)	2 (0.4)	1 (0.2)	3 (0.5)
MUSCLE TENDERNESS	0 (0)	1 (0.2)	0 (0)	1 (0.2)
SKIN RASHES	0 (0)	1 (0.2)	0 (0)	1 (0.2)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.4

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
RECONSTRUCTION PATIENTS

Rheumatologic Physical Finding	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Physical Finding	5 (2.0)	8 (3.2)	1 (0.4)	13 (5.2)
WEAK HEADLIFT	0 (0)	2 (0.8)	0 (0)	2 (0.8)
INABILITY TO RAISE ARMS	0 (0)	1 (0.4)	0 (0)	1 (0.4)
INABILITY TO GET OUT OF CHAIR	0 (0)	1 (0.4)	0 (0)	1 (0.4)
WRIST SWELLING	0 (0)	1 (0.4)	0 (0)	1 (0.4)
DIGITS SWELLING	3 (1.2)	2 (0.8)	0 (0)	5 (2.0)
ELBOWS SWELLING	0 (0)	2 (0.8)	0 (0)	2 (0.8)
KNEES SWELLING	1 (0.4)	2 (0.8)	0 (0)	3 (1.2)
ANKLES SWELLING	1 (0.4)	2 (0.8)	0 (0)	3 (1.2)
TRIGGER FINGERS	0 (0)	1 (0.4)	0 (0)	1 (0.4)
JOINT TENDERNESS	1 (0.4)	3 (1.2)	1 (0.4)	5 (2.0)
GRIP STRENGTH AND MOTION-FINGER TO PALM CREASE	0 (0)	1 (0.4)	0 (0)	1 (0.4)
NECK MOTION-CHIN TO CHEST OR STERNUM	1 (0.4)	1 (0.4)	0 (0)	2 (0.8)
OCCIPUT TO WALL	1 (0.4)	1 (0.4)	0 (0)	2 (0.8)
BACK MOTION	0 (0)	1 (0.4)	0 (0)	1 (0.4)
HAIR LOSS	0 (0)	1 (0.4)	0 (0)	1 (0.4)
SWOLLEN DIGITS	2 (0.8)	2 (0.8)	0 (0)	4 (1.6)
TENDERNESS-INSERTION OF DELTOIDS	0 (0)	1 (0.4)	0 (0)	1 (0.4)

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_4.SAS

Creation Date, Time: 27JUL04 11:48

(a) Includes only rheumatologic physical findings that had an onset date during the time period of interest.

Table 11.4

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
REVISION PATIENTS

Rheumatologic Physical Finding	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Physical Finding	7 (3.4)	9 (4.4)	3 (1.5)	18 (8.8)
WEAK HEADLIFT	1 (0.5)	0 (0)	0 (0)	1 (0.5)
INABILITY TO RAISE ARMS	1 (0.5)	0 (0)	0 (0)	1 (0.5)
DIGITS SWELLING	1 (0.5)	2 (1.0)	1 (0.5)	4 (2.0)
ELBOWS SWELLING	0 (0)	1 (0.5)	0 (0)	1 (0.5)
KNEES SWELLING	0 (0)	2 (1.0)	1 (0.5)	3 (1.5)
ANKLES SWELLING	0 (0)	1 (0.5)	0 (0)	1 (0.5)
BOUTONNIERE	0 (0)	1 (0.5)	0 (0)	1 (0.5)
TRIGGER FINGERS	0 (0)	0 (0)	1 (0.5)	1 (0.5)
JOINT TENDERNESS	3 (1.5)	5 (2.4)	0 (0)	8 (3.9)
NECK MOTION-CHIN TO CHEST OR STERNUM	1 (0.5)	0 (0)	0 (0)	1 (0.5)
BACK MOTION	1 (0.5)	0 (0)	0 (0)	1 (0.5)
HAIR LOSS	2 (1.0)	1 (0.5)	0 (0)	3 (1.5)
RAYNAUD'S PHENOMENON	1 (0.5)	0 (0)	0 (0)	1 (0.5)
SWOLLEN DIGITS	0 (0)	1 (0.5)	0 (0)	1 (0.5)
MUSCLE TENDERNESS	0 (0)	1 (0.5)	0 (0)	1 (0.5)
TINELS OR PHALENS SIGNS	0 (0)	1 (0.5)	0 (0)	1 (0.5)

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.4

INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
OVERALL PATIENTS

Rheumatologic Physical Finding	0-12 months (a)	>12-24 months (a)	>24-36 months (a)	0-36 months (a)
	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)	Number of Patients n(%)
Total with at Least One New Rheumatologic Physical Finding	17 (1.7)	24 (2.4)	10 (1.0)	47 (4.7)
WEAK HEADLIFT	2 (0.2)	2 (0.2)	0 (0)	4 (0.4)
INABILITY TO RAISE ARMS	1 (0.1)	1 (0.1)	0 (0)	2 (0.2)
INABILITY TO GET OUT OF CHAIR	0 (0)	1 (0.1)	0 (0)	1 (0.1)
WRIST SWELLING	1 (0.1)	1 (0.1)	0 (0)	2 (0.2)
DIGITS SWELLING	6 (0.6)	5 (0.5)	2 (0.2)	13 (1.3)
ELBOWS SWELLING	0 (0)	3 (0.3)	0 (0)	3 (0.3)
KNEES SWELLING	2 (0.2)	4 (0.4)	2 (0.2)	8 (0.8)
ANKLES SWELLING	1 (0.1)	4 (0.4)	0 (0)	5 (0.5)
BOUTTONIERE	0 (0)	1 (0.1)	0 (0)	1 (0.1)
TRIGGER FINGERS	0 (0)	1 (0.1)	1 (0.1)	2 (0.2)
JOINT TENDERNESS	5 (0.5)	11 (1.1)	4 (0.4)	20 (2.0)
GRIP STRENGTH AND MOTION FINGER TO PALM CREASE	0 (0)	1 (0.1)	0 (0)	1 (0.1)
NECK MOTION-CHIN TO CHEST OR STERNUM	2 (0.2)	1 (0.1)	0 (0)	3 (0.3)
OCCIPUT TO WALL	1 (0.1)	1 (0.1)	0 (0)	2 (0.2)
BACK MOTION	1 (0.1)	1 (0.1)	0 (0)	2 (0.2)
HAIR LOSS	2 (0.2)	2 (0.2)	1 (0.1)	5 (0.5)
RAYNAUD'S PHENOMENON	1 (0.1)	0 (0)	0 (0)	1 (0.1)
SWOLLEN DIGITS	2 (0.2)	4 (0.4)	0 (0)	6 (0.6)
PAINLESS EYE REDNESS	0 (0)	2 (0.2)	1 (0.1)	3 (0.3)
TENDERNESS-INSERTION OF DELTOIDS	0 (0)	1 (0.1)	0 (0)	1 (0.1)
MUSCLE TENDERNESS	0 (0)	2 (0.2)	0 (0)	2 (0.2)
TINELS OR PHALENS SIGNS	0 (0)	1 (0.1)	0 (0)	1 (0.1)
SKIN RASHES	0 (0)	1 (0.1)	0 (0)	1 (0.1)

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_4.SAS

Creation Date, Time. 27JUL04 11:48

(a) Includes only rheumatologic physical findings that had an onset date during the time period of interest.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.5

CUMMULATIVE INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
AUGMENTATION PATIENTS

Type of Diagnoses	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)
CONNECTIVE TISSUE DISORDERS:						
SLE	0	0.0000	0	0.0000	0	0.0000
SJOGREN'S SYNDROME	0	0.0000	0	0.0000	0	0.0000
SCLERODERMA	0	0.0000	0	0.0000	0	0.0000
POLYMYOSITIS	0	0.0000	0	0.0000	0	0.0000
OTHER CONN TISSUE DISORDERS	0	0.0000	0	0.0000	0	0.0000
INFLAMMATORY ARTHRITIS:						
RHEUMATOID ARTHRITIS	0	0.0000	1	0.0019	1	0.0019
CRYSTALLINE ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
INFECTIOUS ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
SPONDYARTHROPATHIES	0	0.0000	0	0.0000	0	0.0000
OTHER INFLAMM ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
NON-INFLAMMATORY RHEUMATIC CONDITIONS:						
FIBROMYALGIA	0	0.0000	0	0.0000	0	0.0000
CHRONIC FATIGUE	0	0.0000	0	0.0000	0	0.0000
OTHERS:						
HASHIMOTO'S THYROIDITIS	0	0.0000	1	0.0019	1	0.0019
HYPOTHYROIDISM	0	0.0000	1	0.0019	1	0.0019
PYODERMA GANGRENOsum	0	0.0000	0	0.0000	0	0.0000
RIGHT SHOULDER PAIN	0	0.0000	0	0.0000	0	0.0000
Any of the Above	0	0.0000	3	0.0057	3	0.0057
Total Patients Assessed	551		551		551	

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.5

CUMULATIVE INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
RECONSTRUCTION PATIENTS

Type of Diagnoses	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)
CONNECTIVE TISSUE DISORDERS:						
SLE	0	0.0000	0	0.0000	0	0.0000
SJOGREN'S SYNDROME	0	0.0000	0	0.0000	0	0.0000
SCLERODERMA	0	0.0000	0	0.0000	0	0.0000
POLYMYOSITIS	0	0.0000	0	0.0000	0	0.0000
OTHER CONN TISSUE DISORDERS	0	0.0000	0	0.0000	0	0.0000
INFLAMMATORY ARTHRITIS:						
RHEUMATOID ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
CRYSTALLINE ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
INFECTIOUS ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
SPONDYARTHROPATHIES	0	0.0000	0	0.0000	0	0.0000
OTHER INFLAMM ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
NON-INFLAMMATORY RHEUMATIC CONDITIONS:						
FIBROMYALGIA	1	0.0042	1	0.0042	1	0.0042
CHRONIC FATIGUE	0	0.0000	0	0.0000	0	0.0000
OTHERS:						
HASHIMOTO'S THYROIDITIS	0	0.0000	0	0.0000	0	0.0000
HYPOTHYROIDISM	0	0.0000	0	0.0000	0	0.0000
PYODERMA GANGRENOsum	0	0.0000	0	0.0000	0	0.0000
RIGHT SHOULDER PAIN	0	0.0000	0	0.0000	0	0.0000
Any of the Above	1	0.0042	1	0.0042	1	0.0042
Total Patients Assessed	251		251		251	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_5.SAS

Creation Date, Time: 26JUL04 17:07

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.5

CUMULATIVE INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
REVISION PATIENTS

Type of Diagnoses	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)
CONNECTIVE TISSUE DISORDERS:						
SLE	0	0.0000	0	0.0000	0	0.0000
SJOGREN'S SYNDROME	0	0.0000	0	0.0000	0	0.0000
SCLERODERMA	0	0.0000	0	0.0000	0	0.0000
POLYMYOSITIS	0	0.0000	0	0.0000	0	0.0000
OTHER CONN TISSUE DISORDERS	0	0.0000	0	0.0000	0	0.0000
INFLAMMATORY ARTHRITIS:						
RHEUMATOID ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
CRYSTALLINE ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
INFECTIOUS ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
SPONDYARTHROPATHIES	0	0.0000	0	0.0000	0	0.0000
OTHER INFLAMM ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
NON-INFLAMMATORY RHEUMATIC CONDITIONS:						
FIBROMYALGIA	1	0.0050	1	0.0050	1	0.0050
CHRONIC FATIGUE	0	0.0000	0	0.0000	0	0.0000
OTHERS:						
HASHIMOTO'S THYROIDITIS	0	0.0000	0	0.0000	0	0.0000
HYPOTHYROIDISM	0	0.0000	0	0.0000	0	0.0000
PYODERMA GANGRENOSUM	1	0.0051	1	0.0051	1	0.0051
RIGHT SHOULDER PAIN	0	0.0000	0	0.0000	0	0.0000
Any of the Above	2	0.0099	2	0.0099	2	0.0099
Total Patients Assessed	205		205		205	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_5.SAS
(a) Time from implant surgery to first occurrence of event.
(b) Based on Kaplan-Meier Estimates.

Creation Date, Time: 26JUL04 17:07

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.5

CUMULATIVE INCIDENCE OF RHEUMATIC DISEASE NEWLY DIAGNOSED BY A RHEUMATOLOGIST
OVERALL PATIENTS

Type of Diagnoses	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)	Number with Diagnosis	Estimated Proportion with Diagnoses (b)
CONNECTIVE TISSUE DISORDERS:						
SLE	0	0.0000	0	0.0000	0	0.0000
SJOGREN'S SYNDROME	0	0.0000	0	0.0000	0	0.0000
SCLERODERMA	0	0.0000	0	0.0000	0	0.0000
POLYMYOSITIS	0	0.0000	0	0.0000	0	0.0000
OTHER CONN TISSUE DISORDERS	0	0.0000	0	0.0000	0	0.0000
INFLAMMATORY ARTHRITIS:						
RHEUMATOID ARTHRITIS	0	0.0000	1	0.0011	1	0.0011
CRYSTALLINE ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
INFECTIOUS ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
SPONDYARTHROPATHIES	0	0.0000	0	0.0000	0	0.0000
OTHER INFLAMM ARTHRITIS	0	0.0000	0	0.0000	0	0.0000
NON-INFLAMMATORY RHEUMATIC CONDITIONS:						
FIBROMYALGIA	2	0.0020	2	0.0020	2	0.0020
CHRONIC FATIGUE	0	0.0000	0	0.0000	0	0.0000
OTHERS:						
HASHIMOTO'S THYROIDITIS	0	0.0000	1	0.0011	1	0.0011
HYPOTHYROIDISM	0	0.0000	1	0.0011	1	0.0011
PYODERMA GANGRENOSUM	1	0.0010	1	0.0010	1	0.0010
RIGHT SHOULDER PAIN	0	0.0000	0	0.0000	0	0.0000
Any of the Above	3	0.0030	6	0.0062	6	0.0062
Total Patients Assessed	1007		1007		1007	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_5.SAS

Creation Date, Time: 26JUL04 17:07

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.6

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYSTEM CATEGORY
AUGMENTATION PATIENTS

System Category	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)
Skin and Appendages	2	0.0037	6	0.0113	10	0.0213
Muscle	6	0.0110	13	0.0244	18	0.0373
Joint	3	0.0055	11	0.0205	14	0.0285
CNS	7	0.0128	15	0.0279	20	0.0407
Gastrointestinal	1	0.0018	3	0.0056	4	0.0081
Body as a Whole	4	0.0073	14	0.0262	18	0.0357
Metabolic and Nutritional	0	0.0000	1	0.0019	2	0.0044
Hearing and Vestibular	1	0.0018	6	0.0115	7	0.0140
Respiratory	0	0.0000	2	0.0038	2	0.0038
Platelet, Bleeding, Clotting Disorder	1	0.0018	1	0.0018	2	0.0043
Cardiovascular	1	0.0018	1	0.0018	1	0.0018
Vision	2	0.0037	4	0.0074	4	0.0074
Any of the Above	21	0.0383	44	0.0821	51	0.0992
Total Patients Assessed	551		551		551	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_6.SAS
(a) Time from implant surgery to first occurrence of event.
(b) Based on Kaplan-Meier Estimates.

Creation Date, Time. 27JUL04 11:54

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.6

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYSTEM CATEGORY
RECONSTRUCTION PATIENTS

System Category	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)
Skin and Appendages	1	0.0040	1	0.0040	2	0.0124
Muscle	6	0.0249	12	0.0518	14	0.0718
Joint	9	0.0375	15	0.0646	15	0.0646
CNS	1	0.0043	3	0.0131	4	0.0214
Gastrointestinal	0	0.0000	0	0.0000	1	0.0084
Body as a Whole	6	0.0249	15	0.0712	17	0.0877
Metabolic and Nutritional	1	0.0043	1	0.0043	1	0.0043
Hearing and Vestibular	0	0.0000	1	0.0046	1	0.0046
Respiratory	0	0.0000	0	0.0000	0	0.0000
Platelet, Bleeding, Clotting Disorder	0	0.0000	1	0.0047	1	0.0047
Cardiovascular	0	0.0000	0	0.0000	0	0.0000
Vision	1	0.0040	2	0.0084	2	0.0084
Any of the Above	20	0.0825	36	0.1601	40	0.1976
Total Patients Assessed	251		251		251	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_6.SAS

Creation Date, Time: 27JUL04 11:54

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.6

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYSTEM CATEGORY
REVISION PATIENTS

System Category	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)
Skin and Appendages	3	0.0149	5	0.0255	8	0.0511
Muscle	5	0.0248	12	0.0619	15	0.0837
Joint	4	0.0198	10	0.0531	10	0.0531
CNS	5	0.0248	13	0.0668	14	0.0732
Gastrointestinal	2	0.0099	5	0.0257	5	0.0257
Body as a Whole	11	0.0546	22	0.1127	23	0.1200
Metabolic and Nutritional	1	0.0050	3	0.0156	3	0.0156
Hearing and Vestibular	3	0.0148	4	0.0201	5	0.0267
Respiratory	0	0.0000	1	0.0053	1	0.0053
Platelet, Bleeding, Clotting Disorder	1	0.0050	3	0.0155	4	0.0220
Cardiovascular	0	0.0000	0	0.0000	0	0.0000
Vision	0	0.0000	2	0.0107	2	0.0107
Any of the Above	17	0.0842	31	0.1585	36	0.1982
Total Patients Assessed	205		205		205	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_6.SAS
(a) Time from implant surgery to first occurrence of event.
(b) Based on Kaplan-Meier Estimates.

Creation Date, Time: 27JUL04 11.54

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.6

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYSTEM CATEGORY
OVERALL PATIENTS

System Category	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)	Number with System Category	Estimated Proportion with System Category (b)
Skin and Appendages	6	0.0061	12	0.0126	20	0.0255
Muscle	17	0.0172	37	0.0387	47	0.0545
Joint	16	0.0162	36	0.0379	39	0.0431
CNS	13	0.0132	31	0.0323	38	0.0432
Gastrointestinal	3	0.0030	8	0.0083	10	0.0114
Body as a Whole	21	0.0212	51	0.0536	58	0.0639
Metabolic and Nutritional	2	0.0021	5	0.0053	6	0.0068
Hearing and Vestibular	4	0.0040	11	0.0117	13	0.0147
Respiratory	0	0.0000	3	0.0032	3	0.0032
Platelet, Bleeding, Clotting Disorder	2	0.0020	5	0.0052	7	0.0082
Cardiovascular	1	0.0010	1	0.0010	1	0.0010
Vision	3	0.0030	8	0.0083	8	0.0083
Any of the Above	58	0.0585	111	0.1158	127	0.1407
Total Patients Assessed	1007		1007		1007	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_6.SAS

Creation Date, Time: 27JUL04 11.54

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
AUGMENTATION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
LOSS OF WEIGHT WITHOUT DIETING	0	0.0000	1	0.0019	2	0.0044
FATIGUE	1	0.0018	7	0.0132	9	0.0177
INSOMNIA	2	0.0037	7	0.0131	8	0.0153
WEAKNESS	1	0.0018	3	0.0056	3	0.0056
EXHAUSTION	1	0.0018	4	0.0075	5	0.0100
JOINT SWELLING	1	0.0018	4	0.0075	4	0.0075
HEEL PAIN	1	0.0018	3	0.0056	5	0.0108
FREQUENT MUSCLE CRAMPS	1	0.0018	4	0.0075	5	0.0100
NUMBNESS OF FEET	1	0.0018	4	0.0075	5	0.0100
RINGING IN EARS	1	0.0018	6	0.0115	7	0.0140
PAIN/GRITTIENESS IN EYES	2	0.0037	3	0.0055	3	0.0055
DRYNESS OF EYES/NOSE	0	0.0000	1	0.0019	1	0.0019
PAIN ON SWALLOWING OR CHEWING	0	0.0000	0	0.0000	0	0.0000
NECK PAIN/STIFFNESS	3	0.0055	6	0.0112	9	0.0188
PAIN ON BREATHING	0	0.0000	0	0.0000	0	0.0000
HEART MURMURS	1	0.0018	1	0.0018	1	0.0018
LOSS OF APPETITE	0	0.0000	1	0.0019	1	0.0019
PERSISTENT FEVER	0	0.0000	0	0.0000	0	0.0000
NIGHT SWEATS	2	0.0036	5	0.0093	7	0.0143
GENERALIZED ACHING	0	0.0000	4	0.0075	5	0.0105
LOSS OF HEIGHT	0	0.0000	0	0.0000	0	0.0000

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11:59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
AUGMENTATION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
JOINT PAIN	2	0.0037	9	0.0168	12	0.0248
FREQUENT MUSCLE PAIN	0	0.0000	2	0.0038	2	0.0038
NUMBNESS OF HANDS	5	0.0091	10	0.0185	13	0.0266
JAW PAIN	0	0.0000	0	0.0000	0	0.0000
OPEN SORES	0	0.0000	0	0.0000	0	0.0000
REDNESS OF EYES	0	0.0000	1	0.0019	2	0.0044
DRYNESS OF MOUTH	0	0.0000	1	0.0019	1	0.0019
BACK PAIN/STIFFNESS	2	0.0036	6	0.0114	6	0.0114
SEVERE CHEST PAINS	1	0.0018	2	0.0037	2	0.0037
CHRONIC COUGH	0	0.0000	2	0.0038	2	0.0038
DIFFICULTY SWALLOWING	0	0.0000	0	0.0000	0	0.0000
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	1	0.0018	2	0.0037	3	0.0062
SEVERE RASHES	1	0.0018	3	0.0056	3	0.0056
SEVERE DRYNESS OF SKIN	1	0.0018	1	0.0018	3	0.0068
TENDER LUMPS/BUMPS	0	0.0000	1	0.0019	1	0.0019
EXCESSIVE SENSITIVITY TO SUN	0	0.0000	0	0.0000	0	0.0000
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	0	0.0000	0	0.0000	0	0.0000
FREQUENT HIVES	0	0.0000	1	0.0020	1	0.0020
TIGHTNESS OF SKIN	0	0.0000	0	0.0000	0	0.0000
UNUSUAL HAIR LOSS	0	0.0000	1	0.0019	3	0.0069

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11:59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
AUGMENTATION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
TENDERNESS OF SCALP	0	0.0000	0	0.0000	0	0.0000
SEVERE BRUISING WITH LITTLE OR NO INJURY	1	0.0018	1	0.0018	2	0.0043
Any of the Above	21	0.0383	44	0.0821	51	0.0992
Total Patients Assessed	551		551		551	

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
LOSS OF WEIGHT WITHOUT DIETING	1	0.0043	1	0.0043	1	0.0043
FATIGUE	2	0.0083	6	0.0286	7	0.0371
INSOMNIA	1	0.0043	3	0.0131	4	0.0214
WEAKNESS	0	0.0000	0	0.0000	1	0.0084
EXHAUSTION	0	0.0000	2	0.0090	2	0.0090
JOINT SWELLING	2	0.0085	5	0.0227	5	0.0227
HEEL PAIN	0	0.0000	1	0.0046	2	0.0130
FREQUENT MUSCLE CRAMPS	3	0.0125	8	0.0351	8	0.0351
NUMBNESS OF FEET	0	0.0000	0	0.0000	0	0.0000
RINGING IN EARS	0	0.0000	1	0.0046	1	0.0046
PAIN/GRITTIENESS IN EYES	1	0.0040	2	0.0084	2	0.0084
DRYNESS OF EYES/NOSE	1	0.0040	2	0.0084	2	0.0084
PAIN ON SWALLOWING OR CHEWING	0	0.0000	0	0.0000	0	0.0000
NECK PAIN/STIFFNESS	0	0.0000	2	0.0090	4	0.0299
PAIN ON BREATHING	0	0.0000	0	0.0000	0	0.0000
HEART MURMURS	0	0.0000	0	0.0000	0	0.0000
LOSS OF APPETITE	0	0.0000	0	0.0000	0	0.0000
PERSISTENT FEVER	0	0.0000	0	0.0000	0	0.0000
NIGHT SWEATS	2	0.0084	4	0.0194	5	0.0277
GENERALIZED ACHING	1	0.0042	3	0.0130	3	0.0130
LOSS OF HEIGHT	2	0.0085	4	0.0175	4	0.0175

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11.59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
JOINT PAIN	9	0.0375	14	0.0602	14	0.0602
FREQUENT MUSCLE PAIN	2	0.0084	3	0.0128	3	0.0128
NUMBNESS OF HANDS	0	0.0000	0	0.0000	0	0.0000
JAW PAIN	0	0.0000	0	0.0000	1	0.0084
OPEN SORES	0	0.0000	0	0.0000	0	0.0000
REDNESS OF EYES	0	0.0000	0	0.0000	0	0.0000
DRYNESS OF MOUTH	0	0.0000	0	0.0000	0	0.0000
BACK PAIN/STIFFNESS	2	0.0083	3	0.0127	3	0.0127
SEVERE CHEST PAINS	0	0.0000	0	0.0000	0	0.0000
CHRONIC COUGH	0	0.0000	0	0.0000	0	0.0000
DIFFICULTY SWALLOWING	0	0.0000	0	0.0000	0	0.0000
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	0	0.0000	0	0.0000	1	0.0084
SEVERE RASHES	0	0.0000	0	0.0000	0	0.0000
SEVERE DRYNESS OF SKIN	0	0.0000	0	0.0000	0	0.0000
TENDER LUMPS/BUMPS	0	0.0000	1	0.0068	1	0.0068
EXCESSIVE SENSITIVITY TO SUN	0	0.0000	0	0.0000	0	0.0000
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	0	0.0000	0	0.0000	0	0.0000
FREQUENT HIVES	0	0.0000	0	0.0000	0	0.0000
TIGHTNESS OF SKIN	0	0.0000	0	0.0000	0	0.0000
UNUSUAL HAIR LOSS	1	0.0040	1	0.0040	2	0.0124

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11:59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
TENDERNESS OF SCALP	1	0.0043	1	0.0043	1	0.0043
SEVERE BRUISING WITH LITTLE OR NO INJURY	0	0.0000	1	0.0047	1	0.0047
Any of the Above	20	0.0825	36	0.1601	40	0.1976
Total Patients Assessed	251		251		251	

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
REVISION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
LOSS OF WEIGHT WITHOUT DIETING	1	0.0050	3	0.0156	3	0.0156
FATIGUE	5	0.0249	9	0.0460	11	0.0595
INSOMNIA	2	0.0099	5	0.0258	5	0.0258
WEAKNESS	1	0.0050	4	0.0209	5	0.0275
EXHAUSTION	1	0.0050	5	0.0262	6	0.0327
JOINT SWELLING	0	0.0000	3	0.0164	4	0.0229
HEEL PAIN	2	0.0099	2	0.0099	2	0.0099
FREQUENT MUSCLE CRAMPS	1	0.0050	4	0.0206	5	0.0278
NUMBNESS OF FEET	2	0.0099	3	0.0160	4	0.0225
RINGING IN EARS	3	0.0148	4	0.0201	5	0.0267
PAIN/GRITTIENESS IN EYES	0	0.0000	0	0.0000	0	0.0000
DRYNESS OF EYES/NOSE	1	0.0050	2	0.0102	2	0.0102
PAIN ON SWALLOWING OR CHEWING	0	0.0000	2	0.0107	2	0.0107
NECK PAIN/STIFFNESS	3	0.0149	4	0.0202	4	0.0202
PAIN ON BREATHING	0	0.0000	1	0.0053	1	0.0053
HEART MURMURS	0	0.0000	0	0.0000	0	0.0000
LOSS OF APPETITE	0	0.0000	2	0.0106	2	0.0106
PERSISTENT FEVER	0	0.0000	0	0.0000	0	0.0000
NIGHT SWEATS	3	0.0148	4	0.0200	4	0.0200
GENERALIZED ACHING	2	0.0099	6	0.0321	7	0.0387
LOSS OF HEIGHT	0	0.0000	1	0.0053	1	0.0053

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11:59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
REVISION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
JOINT PAIN	4	0.0198	10	0.0531	10	0.0531
FREQUENT MUSCLE PAIN	2	0.0099	2	0.0099	2	0.0099
NUMBNESS OF HANDS	1	0.0050	7	0.0366	8	0.0431
JAW PAIN	1	0.0050	1	0.0050	1	0.0050
OPEN SORES	0	0.0000	0	0.0000	0	0.0000
REDNESS OF EYES	0	0.0000	2	0.0107	2	0.0107
DRYNESS OF MOUTH	1	0.0050	2	0.0103	2	0.0103
BACK PAIN/STIFFNESS	2	0.0099	6	0.0321	8	0.0469
SEVERE CHEST PAINS	0	0.0000	0	0.0000	0	0.0000
CHRONIC COUGH	0	0.0000	0	0.0000	0	0.0000
DIFFICULTY SWALLOWING	0	0.0000	2	0.0107	2	0.0107
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	2	0.0099	4	0.0204	4	0.0204
SEVERE RASHES	0	0.0000	0	0.0000	0	0.0000
SEVERE DRYNESS OF SKIN	1	0.0050	3	0.0156	5	0.0328
TENDER LUMPS/BUMPS	2	0.0099	4	0.0203	5	0.0269
EXCESSIVE SENSITIVITY TO SUN	1	0.0050	1	0.0050	1	0.0050
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	1	0.0050	2	0.0101	2	0.0101
FREQUENT HIVES	1	0.0049	1	0.0049	1	0.0049
TIGHTNESS OF SKIN	0	0.0000	0	0.0000	0	0.0000
UNUSUAL HAIR LOSS	1	0.0051	2	0.0103	3	0.0188

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11.59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
REVISION PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
TENDERNESS OF SCALP	1	0.0049	1	0.0049	1	0.0049
SEVERE BRUISING WITH LITTLE OR NO INJURY	1	0.0050	3	0.0155	4	0.0220
Any of the Above	17	0.0842	31	0.1585	36	0.1982
Total Patients Assessed	205		205		205	

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
OVERALL PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
LOSS OF WEIGHT WITHOUT DIETING	2	0.0021	5	0.0053	6	0.0068
FATIGUE	8	0.0081	22	0.0232	27	0.0304
INSOMNIA	5	0.0051	15	0.0158	17	0.0186
WEAKNESS	2	0.0020	7	0.0074	9	0.0103
EXHAUSTION	2	0.0020	11	0.0116	13	0.0146
JOINT SWELLING	3	0.0030	12	0.0128	13	0.0142
HEEL PAIN	3	0.0030	6	0.0062	9	0.0109
FREQUENT MUSCLE CRAMPS	5	0.0051	16	0.0167	18	0.0198
NUMBNESS OF FEET	3	0.0030	7	0.0076	9	0.0105
RINGING IN EARS	4	0.0040	11	0.0117	13	0.0147
PAIN/GRITTIENESS IN EYES	3	0.0030	5	0.0051	5	0.0051
DRYNESS OF EYES/NOSE	2	0.0020	5	0.0052	5	0.0052
PAIN ON SWALLOWING OR CHEWING	0	0.0000	2	0.0022	2	0.0022
NECK PAIN/STIFFNESS	6	0.0061	12	0.0125	17	0.0206
PAIN ON BREATHING	0	0.0000	1	0.0011	1	0.0011
HEART MURMURS	1	0.0010	1	0.0010	1	0.0010
LOSS OF APPETITE	0	0.0000	3	0.0032	3	0.0032
PERSISTENT FEVER	0	0.0000	0	0.0000	0	0.0000
NIGHT SWEATS	7	0.0070	13	0.0136	16	0.0181
GENERALIZED ACHING	3	0.0030	13	0.0140	15	0.0174
LOSS OF HEIGHT	2	0.0021	5	0.0052	5	0.0052

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11.59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
OVERALL PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
JOINT PAIN	15	0.0152	33	0.0348	36	0.0400
FREQUENT MUSCLE PAIN	4	0.0040	7	0.0072	7	0.0072
NUMBNESS OF HANDS	6	0.0060	17	0.0178	21	0.0243
JAW PAIN	1	0.0010	1	0.0010	2	0.0025
OPEN SORES	0	0.0000	0	0.0000	0	0.0000
REDNESS OF EYES	0	0.0000	3	0.0032	4	0.0047
DRYNESS OF MOUTH	1	0.0010	3	0.0032	3	0.0032
BACK PAIN/STIFFNESS	6	0.0060	15	0.0161	17	0.0192
SEVERE CHEST PAINS	1	0.0010	2	0.0021	2	0.0021
CHRONIC COUGH	0	0.0000	2	0.0021	2	0.0021
DIFFICULTY SWALLOWING	0	0.0000	2	0.0022	2	0.0022
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	3	0.0030	6	0.0062	8	0.0092
SEVERE RASHES	1	0.0010	3	0.0032	3	0.0032
SEVERE DRYNESS OF SKIN	2	0.0020	4	0.0042	8	0.0107
TENDER LUMPS/BUMPS	2	0.0020	6	0.0065	7	0.0079
EXCESSIVE SENSITIVITY TO SUN	1	0.0010	1	0.0010	1	0.0010
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	1	0.0010	2	0.0020	2	0.0020
FREQUENT HIVES	1	0.0010	2	0.0022	2	0.0022
TIGHTNESS OF SKIN	0	0.0000	0	0.0000	0	0.0000
UNUSUAL HAIR LOSS	2	0.0020	4	0.0042	8	0.0105

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_7.SAS

Creation Date, Time: 27JUL04 11:59

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.7

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
OVERALL PATIENTS

Symptom Type	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)
TENDERNESS OF SCALP	2	0.0020	2	0.0020	2	0.0020
SEVERE BRUISING WITH LITTLE OR NO INJURY	2	0.0020	5	0.0052	7	0.0082
Any of the Above	58	0.0585	111	0.1158	127	0.1407
Total Patients Assessed	1007		1007		1007	

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
AUGMENTATION PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
WEAK HEADLIFT	1	0.0018	1	0.0018	1	0.0018
INABILITY TO RAISE ARMS	0	0.0000	0	0.0000	0	0.0000
INABILITY TO GET OUT OF CHAIR	0	0.0000	0	0.0000	0	0.0000
WRIST SWELLING	1	0.0018	1	0.0018	1	0.0018
DIGITS SWELLING	2	0.0037	3	0.0055	4	0.0085
ELBOWS SWELLING	0	0.0000	0	0.0000	0	0.0000
KNEES SWELLING	1	0.0019	1	0.0019	2	0.0048
ANKLES SWELLING	0	0.0000	1	0.0019	1	0.0019
BOUTONNIERE	0	0.0000	0	0.0000	0	0.0000
ULNAR DRIFT	0	0.0000	0	0.0000	0	0.0000
SWAN NECK	0	0.0000	0	0.0000	0	0.0000
TRIGGER FINGERS	0	0.0000	0	0.0000	0	0.0000
JOINT TENDERNESS	1	0.0018	4	0.0075	7	0.0147
GRIP STRENGTH AND MOTION-FINGER TO PALM CREASE	0	0.0000	0	0.0000	0	0.0000
NECK MOTION-CHIN TO CHEST OR STERNUM	0	0.0000	0	0.0000	0	0.0000
CHEST EXPANSION	0	0.0000	0	0.0000	0	0.0000
OCCIPUT TO WALL	0	0.0000	0	0.0000	0	0.0000
JAW MOTION	0	0.0000	0	0.0000	0	0.0000
BACK MOTION	0	0.0000	0	0.0000	0	0.0000
HAIR LOSS	0	0.0000	0	0.0000	1	0.0025

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_8.SAS

Creation Date, Time: 26JUL04 17:10

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
AUGMENTATION PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
SKIN TIGHTNESS	0	0.0000	0	0.0000	0	0.0000
RAYNAUD'S PHENOMENON	0	0.0000	0	0.0000	0	0.0000
CALCINOSIS OVER TIBIA, ULNA, ELBOWS	0	0.0000	0	0.0000	0	0.0000
SWOLLEN DIGITS	0	0.0000	1	0.0019	1	0.0019
ERYTHEMA OVER KNUCKLES	0	0.0000	0	0.0000	0	0.0000
BLuish HUE COLOR ON EYELIDS	0	0.0000	0	0.0000	0	0.0000
NON-TENDER LUMPS OR BUMPS ON ELBOWS	0	0.0000	0	0.0000	0	0.0000
TENDER LUMPS-TIBIA	0	0.0000	0	0.0000	0	0.0000
PAINLESS EYE REDNESS	0	0.0000	2	0.0038	3	0.0063
PAINFUL EYE REDNESS WITH DECREASED VISION, SMALL PUPILS	0	0.0000	0	0.0000	0	0.0000
TENDERNESS-INSERTION OF DELTOIDS	0	0.0000	0	0.0000	0	0.0000
MUSCLE TENDERNESS	0	0.0000	1	0.0019	1	0.0019
NAIL PITTINGS	0	0.0000	0	0.0000	0	0.0000
TINELS OR PHALENS SIGNS	0	0.0000	0	0.0000	0	0.0000
SKIN RASHES	0	0.0000	1	0.0019	1	0.0019
Any of the Above	5	0.0092	12	0.0224	16	0.0322
Total Patients Assessed	551		551		551	

Program Name: O:\MENTOR\COREGEL\3YEAR\TABLES\T11_8.SAS

Creation Date, Time. 26JUL04 17.10

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
RECONSTRUCTION PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
WEAK HEADLIFT	0	0.0000	2	0.0091	2	0.0091
INABILITY TO RAISE ARMS	0	0.0000	1	0.0047	1	0.0047
INABILITY TO GET OUT OF CHAIR	0	0.0000	1	0.0047	1	0.0047
WRIST SWELLING	0	0.0000	1	0.0075	1	0.0075
DIGITS SWELLING	3	0.0126	5	0.0217	5	0.0217
ELBOWS SWELLING	0	0.0000	2	0.0090	2	0.0090
KNEES SWELLING	1	0.0042	3	0.0140	3	0.0140
ANKLES SWELLING	1	0.0042	3	0.0132	3	0.0132
BOUTTONNIERE	0	0.0000	0	0.0000	0	0.0000
ULNAR DRIFT	0	0.0000	0	0.0000	0	0.0000
SWAN NECK	0	0.0000	0	0.0000	0	0.0000
TRIGGER FINGERS	0	0.0000	1	0.0044	1	0.0044
JOINT TENDERNESS	1	0.0041	4	0.0203	5	0.0279
GRIP STRENGTH AND MOTION-FINGER TO PALM CREASE	0	0.0000	1	0.0047	1	0.0047
NECK MOTION-CHIN TO CHEST OR STERNUM	1	0.0042	2	0.0088	2	0.0088
CHEST EXPANSION	0	0.0000	0	0.0000	0	0.0000
OCCIPUT TO WALL	1	0.0043	2	0.0089	2	0.0089
JAW MOTION	0	0.0000	0	0.0000	0	0.0000
BACK MOTION	0	0.0000	1	0.0047	1	0.0047
HAIR LOSS	0	0.0000	1	0.0050	1	0.0050

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_8.SAS

Creation Date, Time: 26JUL04 17:10

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
RECONSTRUCTION PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
SKIN TIGHTNESS	0	0.0000	0	0.0000	0	0.0000
RAYNAUD'S PHENOMENON	0	0.0000	0	0.0000	0	0.0000
CALCINOSIS OVER TIBIA, ULNA, ELBOWS	0	0.0000	0	0.0000	0	0.0000
SWOLLEN DIGITS	2	0.0084	4	0.0178	4	0.0178
ERYTHEMA OVER KNUCKLES	0	0.0000	0	0.0000	0	0.0000
BLUISH HUE COLOR ON EYELIDS	0	0.0000	0	0.0000	0	0.0000
NON-TENDER LUMPS OR BUMPS ON ELBOWS	0	0.0000	0	0.0000	0	0.0000
TENDER LUMPS-TIBIA	0	0.0000	0	0.0000	0	0.0000
PAINLESS EYE REDNESS	0	0.0000	0	0.0000	0	0.0000
PAINFUL EYE REDNESS WITH DECREASED VISION, SMALL PUPILS	0	0.0000	0	0.0000	0	0.0000
TENDERNESS-INSERTION OF DELTOIDS	0	0.0000	1	0.0047	1	0.0047
MUSCLE TENDERNESS	0	0.0000	0	0.0000	0	0.0000
NAIL PITTINGS	0	0.0000	0	0.0000	0	0.0000
TINELS OR PHALENS SIGNS	0	0.0000	0	0.0000	0	0.0000
SKIN RASHES	0	0.0000	0	0.0000	0	0.0000
Any of the Above	5	0.0209	12	0.0533	13	0.0611
Total Patients Assessed	251		251		251	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_8.SAS

Creation Date, Time: 26JUL04 17:10

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
REVISION PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
WEAK HEADLIFT	1	0.0050	1	0.0050	1	0.0050
INABILITY TO RAISE ARMS	1	0.0050	1	0.0050	1	0.0050
INABILITY TO GET OUT OF CHAIR	0	0.0000	0	0.0000	0	0.0000
WRIST SWELLING	0	0.0000	0	0.0000	0	0.0000
DIGITS SWELLING	1	0.0049	3	0.0162	4	0.0227
ELBOWS SWELLING	0	0.0000	1	0.0053	1	0.0053
KNEES SWELLING	0	0.0000	2	0.0106	3	0.0179
ANKLES SWELLING	0	0.0000	1	0.0054	1	0.0054
BOUTONNIERE	0	0.0000	1	0.0052	1	0.0052
ULNAR DRIFT	0	0.0000	0	0.0000	0	0.0000
SWAN NECK	0	0.0000	0	0.0000	0	0.0000
TRIGGER FINGERS	0	0.0000	0	0.0000	1	0.0074
JOINT TENDERNESS	3	0.0148	8	0.0416	8	0.0416
GRIP STRENGTH AND MOTION-FINGER TO PALM CREASE	0	0.0000	0	0.0000	0	0.0000
NECK MOTION-CHIN TO CHEST OR STERNUM	1	0.0050	1	0.0050	1	0.0050
CHEST EXPANSION	0	0.0000	0	0.0000	0	0.0000
OCCIPUT TO WALL	0	0.0000	0	0.0000	0	0.0000
JAW MOTION	0	0.0000	0	0.0000	0	0.0000
BACK MOTION	1	0.0050	1	0.0050	1	0.0050
HAIR LOSS	2	0.0100	3	0.0152	3	0.0152

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_8.SAS

Creation Date, Time: 26JUL04 17:10

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
REVISION PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
SKIN TIGHTNESS	0	0.0000	0	0.0000	0	0.0000
RAYNAUD'S PHENOMENON	1	0.0050	1	0.0050	1	0.0050
CALCINOSIS OVER TIBIA, ULNA, ELBOWS	0	0.0000	0	0.0000	0	0.0000
SWOLLEN DIGITS	0	0.0000	1	0.0053	1	0.0053
ERYTHEMA OVER KNUCKLES	0	0.0000	0	0.0000	0	0.0000
BLUISH HUE COLOR ON EYELIDS	0	0.0000	0	0.0000	0	0.0000
NON-TENDER LUMPS OR BUMPS ON ELBOWS	0	0.0000	0	0.0000	0	0.0000
TENDER LUMPS-TIBIA	0	0.0000	0	0.0000	0	0.0000
PAINLESS EYE REDNESS	0	0.0000	0	0.0000	0	0.0000
PAINFUL EYE REDNESS WITH DECREASED VISION, SMALL PUPILS	0	0.0000	0	0.0000	0	0.0000
TENDERNESS-INSERTION OF DELTOIDS	0	0.0000	0	0.0000	0	0.0000
MUSCLE TENDERNESS	0	0.0000	1	0.0053	1	0.0053
NAIL PITTINGS	0	0.0000	0	0.0000	0	0.0000
TINELS OR PHALENS SIGNS	0	0.0000	1	0.0051	1	0.0051
SKIN RASHES	0	0.0000	0	0.0000	0	0.0000
Any of the Above	7	0.0347	16	0.0825	18	0.0970
Total Patients Assessed	205		205		205	

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
OVERALL PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
WEAK HEADLIFT	2	0.0020	4	0.0042	4	0.0042
INABILITY TO RAISE ARMS	1	0.0010	2	0.0021	2	0.0021
INABILITY TO GET OUT OF CHAIR	0	0.0000	1	0.0011	1	0.0011
WRIST SWELLING	1	0.0010	2	0.0023	2	0.0023
DIGITS SWELLING	6	0.0061	11	0.0116	13	0.0150
ELBOWS SWELLING	0	0.0000	3	0.0032	3	0.0032
KNEES SWELLING	2	0.0020	6	0.0064	8	0.0099
ANKLES SWELLING	1	0.0010	5	0.0053	5	0.0053
BOUTTONIERE	0	0.0000	1	0.0011	1	0.0011
ULNAR DRIFT	0	0.0000	0	0.0000	0	0.0000
SWAN NECK	0	0.0000	0	0.0000	0	0.0000
TRIGGER FINGERS	0	0.0000	1	0.0011	2	0.0026
JOINT TENDERNESS	5	0.0050	16	0.0171	20	0.0228
GRIP STRENGTH AND MOTION-FINGER TO PALM CREASE	0	0.0000	1	0.0011	1	0.0011
NECK MOTION-CHIN TO CHEST OR STERNUM	2	0.0020	3	0.0031	3	0.0031
CHEST EXPANSION	0	0.0000	0	0.0000	0	0.0000
OCCIPUT TO WALL	1	0.0010	2	0.0021	2	0.0021
JAW MOTION	0	0.0000	0	0.0000	0	0.0000
BACK MOTION	1	0.0010	2	0.0021	2	0.0021
HAIR LOSS	2	0.0020	4	0.0042	5	0.0057

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_8.SAS

Creation Date, Time: 26JUL04 17:10

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.8

CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE RHEUMATOLOGIC PHYSICAL EXAMINATION FINDINGS
OVERALL PATIENTS

Examination Findings	Time from Implant Surgery (a)					
	12 months		24 months		36 months	
	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)	Number with Examination Findings	Estimated Proportion with Examination Findings (b)
SKIN TIGHTNESS	0	0.0000	0	0.0000	0	0.0000
RAYNAUD'S PHENOMENON	1	0.0010	1	0.0010	1	0.0010
CALCINOSIS OVER TIBIA, ULNA, ELBOWS	0	0.0000	0	0.0000	0	0.0000
SWOLLEN DIGITS	2	0.0020	6	0.0063	6	0.0063
ERYTHEMA OVER KNUCKLES	0	0.0000	0	0.0000	0	0.0000
BLUISH HUE COLOR ON EYELIDS	0	0.0000	0	0.0000	0	0.0000
NON-TENDER LUMPS OR BUMPS ON ELBOWS	0	0.0000	0	0.0000	0	0.0000
TENDER LUMPS-TIBIA	0	0.0000	0	0.0000	0	0.0000
PAINLESS EYE REDNESS	0	0.0000	2	0.0021	3	0.0036
PAINFUL EYE REDNESS WITH DECREASED VISION, SMALL PUPILS	0	0.0000	0	0.0000	0	0.0000
TENDERNESS-INSERTION OF DELTOIDS	0	0.0000	1	0.0011	1	0.0011
MUSCLE TENDERNESS	0	0.0000	2	0.0021	2	0.0021
NAIL PITTINGS	0	0.0000	0	0.0000	0	0.0000
TINELS OR PHALENS SIGNS	0	0.0000	1	0.0010	1	0.0010
SKIN RASHES	0	0.0000	1	0.0011	1	0.0011
Any of the Above	17	0.0172	40	0.0419	47	0.0523
Total Patients Assessed	1007		1007		1007	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_8.SAS

Creation Date, Time: 26JUL04 17:10

(a) Time from implant surgery to first occurrence of event.

(b) Based on Kaplan-Meier Estimates.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.9

INCIDENCE OF PATIENT REPORT OF POSTOPERATIVE RHEUMATOLOGICAL SYMPTOMS - FDA Item 8

Symptom Type	Baseline	12 Months		24 Months		36 Months	
		Yes	No	Yes	No	Yes	No
LOSS OF WEIGHT WITHOUT DIETING	Yes	1	3	1	3	0	2
	No	0	835	2	798	1	574
FATIGUE	Yes	7	5	5	4	1	1
	No	6	835	14	798	6	574
INSOMNIA	Yes	12	18	8	20	2	13
	No	4	835	9	798	2	574
WEAKNESS	Yes	1	0	1	0	0	0
	No	2	835	6	798	2	574
EXHAUSTION	Yes	1	0	1	0	0	0
	No	1	835	9	798	3	574
JOINT SWELLING	Yes	4	4	4	4	0	2
	No	3	835	7	798	4	574
HEEL PAIN	Yes	2	1	0	2	1	0
	No	2	835	6	798	2	574
FREQUENT MUSCLE CRAMPS	Yes	2	2	2	2	0	1
	No	4	835	9	798	4	574
NUMBNESS OF FEET	Yes	1	2	1	2	0	1
	No	1	835	7	798	2	574
RINGING IN EARS	Yes	6	8	4	9	2	5

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.9

INCIDENCE OF PATIENT REPORT OF POSTOPERATIVE RHEUMATOLOGICAL SYMPTOMS - FDA Item 8

Symptom Type	Baseline	12 Months		24 Months		36 Months	
		Yes	No	Yes	No	Yes	No
RINGING IN EARS	No	3	835	7	798	4	574
PAIN/GRITTIENESS IN EYES	No	2	835	2	798	1	574
DRYNESS OF EYES/NOSE	Yes	9	8	8	8	2	8
	No	0	835	1	798	1	574
PAIN ON SWALLOWING OR CHEWING	Yes	1	0	1	0	0	0
	No	0	835	2	798	0	574
NECK PAIN/STIFFNESS	Yes	9	12	6	12	3	12
	No	4	835	6	798	6	574
PAIN ON BREATHING	No	0	835	1	798	0	574
HEART MURMURS	Yes	15	22	13	22	3	17
	No	1	835	1	798	1	574
LOSS OF APPETITE	Yes	1	0	1	0	0	0
	No	0	835	3	798	0	574
PERSISTENT FEVER	No	0	835	0	798	0	574
NIGHT SWEATS	Yes	8	13	6	13	1	6
	No	5	835	6	798	4	574
GENERALIZED ACHING	Yes	5	4	6	4	1	3
	No	1	835	8	798	4	574

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.9

INCIDENCE OF PATIENT REPORT OF POSTOPERATIVE RHEUMATOLOGICAL SYMPTOMS - FDA Item 8

Symptom Type	Baseline	12 Months		24 Months		36 Months	
		Yes	No	Yes	No	Yes	No
LOSS OF HEIGHT	Yes	2	2	2	2	0	1
	No	0	835	2	798	0	574
JOINT PAIN	Yes	9	9	9	9	2	4
	No	9	835	18	798	12	574
FREQUENT MUSCLE PAIN	Yes	4	3	2	2	0	3
	No	3	835	5	798	1	574
NUMBNESS OF HANDS	Yes	4	7	3	8	4	6
	No	4	835	12	798	5	574
JAW PAIN	Yes	3	4	3	4	1	3
	No	0	835	0	798	0	574
OPEN SORES	No	0	835	0	798	0	574
REDNESS OF EYES	Yes	3	0	3	0	1	1
	No	0	835	1	798	1	574
DRYNESS OF MOUTH	Yes	1	3	1	2	1	2
	No	1	835	2	798	2	574
BACK PAIN/STIFFNESS	Yes	11	13	10	12	2	9
	No	5	835	12	798	4	574
SEVERE CHEST PAINS	No	1	835	2	798	0	574

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11 9

INCIDENCE OF PATIENT REPORT OF POSTOPERATIVE RHEUMATOLOGICAL SYMPTOMS - FDA Item 8

Symptom Type	Baseline	12 Months		24 Months		36 Months	
		Yes	No	Yes	No	Yes	No
CHRONIC COUGH	Yes	0	1	0	1	0	1
	No	0	835	2	798	0	574
DIFFICULTY SWALLOWING	No	0	835	2	798	0	574
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	Yes	4	5	4	5	2	4
	No	2	835	2	798	2	574
SEVERE RASHES	No	1	835	2	798	0	574
SEVERE DRYNESS OF SKIN	Yes	1	1	2	1	1	0
	No	3	835	1	798	2	574
TENDER LUMPS/BUMPS	Yes	1	1	1	1	0	0
	No	1	835	4	798	1	574
EXCESSIVE SENSITIVITY TO SUN	Yes	2	1	2	1	2	1
	No	0	835	1	798	0	574
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	Yes	8	9	8	9	6	8
	No	1	835	1	798	1	574
FREQUENT HIVES	Yes	0	1	0	0	0	0
	No	0	835	1	798	0	574
TIGHTNESS OF SKIN	Yes	0	1	0	1	0	0
	No	0	835	0	798	0	574

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.9

INCIDENCE OF PATIENT REPORT OF POSTOPERATIVE RHEUMATOLOGICAL SYMPTOMS - FDA Item 8

Symptom Type	Baseline	12 Months		24 Months		36 Months	
		Yes	No	Yes	No	Yes	No
UNUSUAL HAIR LOSS	Yes	3	3	3	3	1	2
	No	1	835	1	798	4	574
TENDERNESS OF SCALP	Yes	0	1	0	1	0	1
	No	0	835	0	798	0	574
SEVERE BRUISING WITH LITTLE OR NO INJURY	Yes	4	5	4	7	1	3
	No	2	835	3	798	3	574

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.10

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYSTEM CATEGORY
AUGMENTATION PATIENTS - FDA Item 7b(1)

System Category	36 Months after Implant Surgery (a)				P-value (d)
	SPS		CoreGel (b)		
	Number with System Category	Estimated Proportion with System Category (c)	Number with System Category	Estimated Proportion with System Category (c)	
Skin and Appendages	54	0.0563	10	0.0213	0.0007
Muscle	147	0.1528	18	0.0373	0.0000
Joint	57	0.0607	14	0.0285	0.0102
CNS	94	0.0996	20	0.0407	0.0001
Gastrointestinal	47	0.0499	4	0.0081	0.0001
Body as a Whole	183	0.1870	18	0.0357	0.0000
Metabolic and Nutritional	15	0.0160	2	0.0044	0.0625
Hearing and Vestibular	19	0.0201	7	0.0140	0.4246
Respiratory	6	0.0066	2	0.0038	0.4666
Platelet, Bleeding, Clotting Disorder	14	0.0147	2	0.0043	0.0606
Vascular System	3	0.0036	0	0.0000	1.0000
Cardiovascular	20	0.0201	1	0.0018	0.0033
Vision	17	0.0169	4	0.0074	0.0995
Any of the Above	329	0.3336	51	0.0992	0.0000
Total Patients Assessed	1264		551		

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_10.SAS

Creation Date, Time: 09AUG04 18.25

(a) Time from implant surgery to first occurrence of event.

(b) Excludes data on revision patients.

(c) Based on Kaplan-Meier estimates.

(d) p-value is from log-rank test of estimated proportion among patients in SPS versus CoreGel.

Note: System categories were reviewed and approved by the FDA for the SPS report.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.10

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYSTEM CATEGORY
RECONSTRUCTION PATIENTS - FDA Item 7b(1)

System Category	36 Months after Implant Surgery (a)				P-value (d)
	SPS		CoreGel (b)		
	Number with	Estimated Proportion	Number with	Estimated Proportion	
	System Category	with System Category (c)	System Category	with System Category (c)	
Skin and Appendages	30	0.1120	2	0.0124	0.0006
Muscle	67	0.2413	14	0.0718	0.0001
Joint	47	0.1974	15	0.0646	0.0594
CNS	45	0.1769	4	0.0214	0.0001
Gastrointestinal	26	0.1015	1	0.0084	0.0023
Body as a Whole	87	0.3384	17	0.0877	0.0000
Metabolic and Nutritional	9	0.0462	1	0.0043	0.1220
Hearing and Vestibular	6	0.0247	1	0.0046	0.1719
Respiratory	6	0.0293	0	0.0000	0.0809
Platelet, Bleeding, Clotting Disorder	7	0.0303	1	0.0047	0.1149
Vascular System	2	0.0081	0	0.0000	1.0000
Cardiovascular	3	0.0103	0	0.0000	0.1585
Vision	8	0.0282	2	0.0084	0.2458
Any of the Above	138	0.5025	40	0.1976	0.0001
Total Patients Assessed	416		251		

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_10.SAS

Creation Date, Time: 09AUG04 18:25

(a) Time from implant surgery to first occurrence of event.

(b) Excludes data on revision patients.

(c) Based on Kaplan-Meier estimates.

(d) p-value is from log-rank test of estimated proportion among patients in SPS versus CoreGel.

Note: System categories were reviewed and approved by the FDA for the SPS report.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.10

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYSTEM CATEGORY
OVERALL PATIENTS - FDA Item 7b(1)

System Category	36 Months after Implant Surgery (a)				P-value (d)
	SPS		CoreGel (b)		
	Number with	Estimated Proportion	Number with	Estimated Proportion	
	System Category	with System Category (c)	System Category	with System Category (c)	
Skin and Appendages	84	0.0687	12	0.0189	0.0000
Muscle	214	0.1735	32	0.0469	0.0000
Joint	104	0.0874	29	0.0404	0.0020
CNS	139	0.1161	24	0.0355	0.0000
Gastrointestinal	73	0.0606	5	0.0078	0.0000
Body as a Whole	270	0.2176	35	0.0497	0.0000
Metabolic and Nutritional	24	0.0206	3	0.0046	0.0197
Hearing and Vestibular	25	0.0212	8	0.0116	0.1656
Respiratory	12	0.0105	2	0.0027	0.0953
Platelet, Bleeding, Clotting Disorder	21	0.0176	3	0.0045	0.0146
Vascular System	5	0.0046	0	0.0000	1.0000
Cardiovascular	23	0.0181	1	0.0013	0.0010
Vision	25	0.0195	6	0.0078	0.0441
Any of the Above	467	0.3706	91	0.1259	0.0000
Total Patients Assessed	1680		802		

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_10.SAS

Creation Date, Time: 09AUG04 18:25

(a) Time from implant surgery to first occurrence of event.

(b) Excludes data on revision patients.

(c) Based on Kaplan-Meier estimates.

(d) p-value is from log-rank test of estimated proportion among patients in SPS versus CoreGel.

Note: System categories were reviewed and approved by the FDA for the SPS report.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
AUGMENTATION PATIENTS - FDA Item 7b(1)

36 Months after Implant Surgery					
Symptom Type	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
LOSS OF WEIGHT WITHOUT DIETING	15	0.0160	2	0.0044	0.0625
FATIGUE	91	0.0948	9	0.0177	0.0000
INSOMNIA	61	0.0653	8	0.0153	0.0002
WEAKNESS	26	0.0281	3	0.0056	0.0196
EXHAUSTION	37	0.0388	5	0.0100	0.0017
JOINT SWELLING	12	0.0134	4	0.0075	0.4970
HEEL PAIN	8	0.0086	5	0.0108	0.8925
FREQUENT MUSCLE CRAMPS	28	0.0289	5	0.0100	0.0208
NUMBNESS OF FEET	14	0.0150	5	0.0100	0.4503
RINGING IN EARS	19	0.0201	7	0.0140	0.4246
PAIN/GRITTIENESS IN EYES	8	0.0079	3	0.0055	0.5823
DRYNESS OF EYES/NOSE	30	0.0318	1	0.0019	0.0003
PAIN ON SWALLOWING OR CHEWING	5	0.0055	0	0.0000	0.0664
NECK PAIN/STIFFNESS	58	0.0619	9	0.0188	0.0001
PAIN ON BREATHING	3	0.0043	0	0.0000	0.2982
HEART MURMURS	20	0.0201	1	0.0018	0.0033
LOSS OF APPETITE	16	0.0174	1	0.0019	0.0292
PERSISTENT FEVER	1	0.0010	0	0.0000	0.5028
NIGHT SWEATS	33	0.0335	7	0.0143	0.0100
GENERALIZED ACHING	22	0.0231	5	0.0105	0.0889
LOSS OF HEIGHT	0	0.0000	0	0.0000	0.5241

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
AUGMENTATION PATIENTS - FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				
	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
JOINT PAIN	48	0.0512	12	0.0248	0.0187
FREQUENT MUSCLE PAIN	8	0.0082	2	0.0038	0.0859
NUMBNESS OF HANDS	26	0.0274	13	0.0266	0.5458
JAW PAIN	21	0.0209	0	0.0000	0.0006
OPEN SORES	1	0.0010	0	0.0000	0.4931
REDNESS OF EYES	8	0.0080	2	0.0044	0.1879
DRYNESS OF MOUTH	15	0.0156	1	0.0019	0.0213
BACK PAIN/STIFFNESS	72	0.0754	6	0.0114	0.0000
SEVERE CHEST PAINS	1	0.0010	2	0.0037	0.2018
CHRONIC COUGH	4	0.0039	2	0.0038	0.6876
DIFFICULTY SWALLOWING	5	0.0059	0	0.0000	0.1660
FREQUENT,SEVERE DIARRHEA/CONSTIPATION	27	0.0280	3	0.0062	0.0053
SEVERE RASHES	4	0.0041	3	0.0056	0.8073
SEVERE DRYNESS OF SKIN	23	0.0247	3	0.0068	0.0278
TENDER LUMPS/BUMPS	8	0.0091	1	0.0019	0.0357
EXCESSIVE SENSITIVITY TO SUN	10	0.0106	0	0.0000	0.0258
COLOR CHANGES ON HANDS/FEET WITH COLD EX	23	0.0247	0	0.0000	0.0004
FREQUENT HIVES	3	0.0030	1	0.0020	0.2995
TIGHTNESS OF SKIN	0	0.0000	0	0.0000	0.5453
UNUSUAL HAIR LOSS	26	0.0272	3	0.0069	0.0032
TENDERNESS OF SCALP	7	0.0069	0	0.0000	0.0485

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
AUGMENTATION PATIENTS FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				
	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
SEVERE BRUISING WITH LITTLE OR NO INJURY	14	0.0147	2	0.0043	0.0606
COMBINED FATIGUE	113	0.1171	9	0.0176	0.0000
COMBINED PAIN	161	0.1683	19	0.0372	0.0000
COMBINED FIBROMYALGIA	74	0.0761	7	0.0133	0.0000
Any of the Above	329	0.3336	51	0.0992	0.0000
Total Patients Assessed	1264		551		

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS - FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				
	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion	Number with Symptom Type	Estimated Proportion	
		with Symptom Type (b)		with Symptom Type (b)	
LOSS OF WEIGHT WITHOUT DIETING	9	0.0462	1	0.0043	0.1220
FATIGUE	42	0.1635	7	0.0371	0.0014
INSOMNIA	22	0.0833	4	0.0214	0.0231
WEAKNESS	17	0.0690	1	0.0084	0.0104
EXHAUSTION	25	0.1061	2	0.0090	0.0035
JOINT SWELLING	9	0.0383	5	0.0227	0.9971
HEEL PAIN	9	0.0354	2	0.0130	0.1865
FREQUENT MUSCLE CRAMPS	20	0.0760	8	0.0351	0.4258
NUMBNESS OF FEET	9	0.0379	0	0.0000	0.0402
RINGING IN EARS	6	0.0247	1	0.0046	0.1719
PAIN/GRITTIENESS IN EYES	2	0.0071	2	0.0084	0.8091
DRYNESS OF EYES/NOSE	14	0.0535	2	0.0084	0.0504
PAIN ON SWALLOWING OR CHEWING	1	0.0034	0	0.0000	0.3643
NECK PAIN/STIFFNESS	24	0.0851	4	0.0299	0.0149
PAIN ON BREATHING	2	0.0095	0	0.0000	0.2758
HEART MURMURS	3	0.0103	0	0.0000	0.1585
LOSS OF APPETITE	10	0.0424	0	0.0000	0.0253
PERSISTENT FEVER	2	0.0069	0	0.0000	0.3415
NIGHT SWEATS	33	0.1353	5	0.0277	0.0029
GENERALIZED ACHING	17	0.0653	3	0.0130	0.0361
LOSS OF HEIGHT	6	0.0324	4	0.0175	0.9362

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS - FDA Item 7b(1)

36 Months after Implant Surgery					
Symptom Type	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
JOINT PAIN	33	0.1426	14	0.0602	0.3658
FREQUENT MUSCLE PAIN	9	0.0312	3	0.0128	0.1418
NUMBNESS OF HANDS	20	0.0845	0	0.0000	0.0019
JAW PAIN	3	0.0155	1	0.0084	0.7904
OPEN SORES	0	0.0000	0	0.0000	
REDNESS OF EYES	6	0.0211	0	0.0000	0.0807
DRYNESS OF MOUTH	14	0.0675	0	0.0000	0.0094
BACK PAIN/STIFFNESS	20	0.0859	3	0.0127	0.0283
SEVERE CHEST PAINS	1	0.0035	0	0.0000	0.3849
CHRONIC COUGH	5	0.0233	0	0.0000	0.1304
DIFFICULTY SWALLOWING	2	0.0068	0	0.0000	0.2609
FREQUENT,SEVERE DIARRHEA/CONSTIPATION	17	0.0650	1	0.0084	0.0288
SEVERE RASHES	2	0.0173	0	0.0000	0.3920
SEVERE DRYNESS OF SKIN	16	0.0562	0	0.0000	0.0034
TENDER LUMPS/BUMPS	5	0.0174	1	0.0068	0.4259
EXCESSIVE SENSITIVITY TO SUN	3	0.0106	0	0.0000	0.1152
COLOR CHANGES ON HANDS/FEET WITH COLD EX	6	0.0263	0	0.0000	0.1004
FREQUENT HIVES	0	0.0000	0	0.0000	
TIGHTNESS OF SKIN	4	0.0145	0	0.0000	0.1714
UNUSUAL HAIR LOSS	9	0.0365	2	0.0124	0.2194
TENDERNESS OF SCALP	2	0.0084	1	0.0043	0.9653

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18.25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
RECONSTRUCTION PATIENTS - FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				P-value (c)
	SPS (a)		CoreGel		
	Number with Symptom Type	Estimated Proportion	Number with Symptom Type	Estimated Proportion	
		with Symptom Type (b)		with Symptom Type (b)	
SEVERE BRUISING WITH LITTLE OR NO INJURY	7	0.0303	1	0.0047	0.1149
COMBINED FATIGUE	53	0.2020	7	0.0371	0.0001
COMBINED PAIN	74	0.2781	23	0.1108	0.0054
COMBINED FIBROMYALGIA	37	0.1322	4	0.0176	0.0005
Any of the Above	138	0.5025	40	0.1976	0.0001
Total Patients Assessed	416		251		

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
REVISION PATIENTS - FDA Item 7b(1)

36 Months after Implant Surgery					
Symptom Type	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
LOSS OF WEIGHT WITHOUT DIETING	0	0.0000	3	0.0156	
FATIGUE	0	0.0000	11	0.0595	
INSOMNIA	0	0.0000	5	0.0258	
WEAKNESS	0	0.0000	5	0.0275	
EXHAUSTION	0	0.0000	6	0.0327	
JOINT SWELLING	0	0.0000	4	0.0229	
HEEL PAIN	0	0.0000	2	0.0099	
FREQUENT MUSCLE CRAMPS	0	0.0000	5	0.0278	
NUMBNESS OF FEET	0	0.0000	4	0.0225	
RINGING IN EARS	0	0.0000	5	0.0267	
PAIN/GRITTIENESS IN EYES	0	0.0000	0	0.0000	
DRYNESS OF EYES/NOSE	0	0.0000	2	0.0102	
PAIN ON SWALLOWING OR CHEWING	0	0.0000	2	0.0107	
NECK PAIN/STIFFNESS	0	0.0000	4	0.0202	
PAIN ON BREATHING	0	0.0000	1	0.0053	
HEART MURMURS	0	0.0000	0	0.0000	
LOSS OF APPETITE	0	0.0000	2	0.0106	
PERSISTENT FEVER	0	0.0000	0	0.0000	
NIGHT SWEATS	0	0.0000	4	0.0200	
GENERALIZED ACHING	0	0.0000	7	0.0387	
LOSS OF HEIGHT	0	0.0000	1	0.0053	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time. 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
REVISION PATIENTS - FDA Item 7b(1)

36 Months after Implant Surgery					
Symptom Type	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
JOINT PAIN	0	0.0000	10	0.0531	
FREQUENT MUSCLE PAIN	0	0.0000	2	0.0099	
NUMBNESS OF HANDS	0	0.0000	8	0.0431	
JAW PAIN	0	0.0000	1	0.0050	
OPEN SORES	0	0.0000	0	0.0000	
REDNESS OF EYES	0	0.0000	2	0.0107	
DRYNESS OF MOUTH	0	0.0000	2	0.0103	
BACK PAIN/STIFFNESS	0	0.0000	8	0.0469	
SEVERE CHEST PAINS	0	0.0000	0	0.0000	
CHRONIC COUGH	0	0.0000	0	0.0000	
DIFFICULTY SWALLOWING	0	0.0000	2	0.0107	
FREQUENT,SEVERE DIARRHEA/CONSTIPATION	0	0.0000	4	0.0204	
SEVERE RASHES	0	0.0000	0	0.0000	
SEVERE DRYNESS OF SKIN	0	0.0000	5	0.0328	
TENDER LUMPS/BUMPS	0	0.0000	5	0.0269	
EXCESSIVE SENSITIVITY TO SUN	0	0.0000	1	0.0050	
COLOR CHANGES ON HANDS/FEET WITH COLD EX	0	0.0000	2	0.0101	
FREQUENT HIVES	0	0.0000	1	0.0049	
TIGHTNESS OF SKIN	0	0.0000	0	0.0000	
UNUSUAL HAIR LOSS	0	0.0000	3	0.0188	
TENDERNESS OF SCALP	0	0.0000	1	0.0049	

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
REVISION PATIENTS - FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				P-value (c)
	SPS (a)		CoreGel		
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
SEVERE BRUISING WITH LITTLE OR NO INJURY	0	0.0000	4	0.0220	
COMBINED FATIGUE	0	0.0000	11	0.0595	
COMBINED PAIN	0	0.0000	18	0.0990	
COMBINED FIBROMYALGIA	0	0.0000	7	0.0359	
Any of the Above	0	0.0000	36	0.1982	
Total Patients Assessed	0		205		

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
OVERALL PATIENTS - FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				
	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion	Number with Symptom Type	Estimated Proportion	
		with Symptom Type (b)		with Symptom Type (b)	
LOSS OF WEIGHT WITHOUT DIETING	24	0.0206	6	0.0068	0.0454
FATIGUE	133	0.1089	27	0.0304	0.0000
INSOMNIA	83	0.0700	17	0.0186	0.0000
WEAKNESS	43	0.0363	9	0.0103	0.0030
EXHAUSTION	62	0.0513	13	0.0146	0.0001
JOINT SWELLING	21	0.0184	13	0.0142	0.8457
HEEL PAIN	17	0.0141	9	0.0109	0.3273
FREQUENT MUSCLE CRAMPS	48	0.0391	18	0.0198	0.0364
NUMBNESS OF FEET	23	0.0195	9	0.0105	0.2119
RINGING IN EARS	25	0.0212	13	0.0147	0.3594
PAIN/GRITTIENESS IN EYES	10	0.0077	5	0.0051	0.4593
DRYNESS OF EYES/NOSE	44	0.0366	5	0.0052	0.0000
PAIN ON SWALLOWING OR CHEWING	6	0.0051	2	0.0022	0.1775
NECK PAIN/STIFFNESS	82	0.0683	17	0.0206	0.0000
PAIN ON BREATHING	5	0.0054	1	0.0011	0.2804
HEART MURMURS	23	0.0181	1	0.0010	0.0002
LOSS OF APPETITE	26	0.0222	3	0.0032	0.0032
PERSISTENT FEVER	3	0.0023	0	0.0000	0.1892
NIGHT SWEATS	66	0.0534	16	0.0181	0.0000
GENERALIZED ACHING	39	0.0318	15	0.0174	0.0477
LOSS OF HEIGHT	6	0.0055	5	0.0052	0.9880

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
OVERALL PATIENTS - FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				
	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with	Number with Symptom Type	Estimated Proportion with	
		Symptom Type (b)		Symptom Type (b)	
JOINT PAIN	81	0.0689	36	0.0400	0.0301
FREQUENT MUSCLE PAIN	17	0.0134	7	0.0072	0.0231
NUMBNESS OF HANDS	46	0.0384	21	0.0243	0.0778
JAW PAIN	24	0.0190	2	0.0025	0.0005
OPEN SORES	1	0.0007	0	0.0000	0.4371
REDNESS OF EYES	14	0.0110	4	0.0047	0.0617
DRYNESS OF MOUTH	29	0.0249	3	0.0032	0.0006
BACK PAIN/STIFFNESS	92	0.0767	17	0.0192	0.0000
SEVERE CHEST PAINS	2	0.0015	2	0.0021	0.8915
CHRONIC COUGH	9	0.0072	2	0.0021	0.1175
DIFFICULTY SWALLOWING	7	0.0065	2	0.0022	0.3193
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	44	0.0358	8	0.0092	0.0007
SEVERE RASHES	6	0.0056	3	0.0032	0.3674
SEVERE DRYNESS OF SKIN	39	0.0323	8	0.0107	0.0020
TENDER LUMPS/BUMPS	13	0.0113	7	0.0079	0.2638
EXCESSIVE SENSITIVITY TO SUN	13	0.0110	1	0.0010	0.0069
COLOR CHANGES ON HANDS/FEET WITH COLD EX	29	0.0250	2	0.0020	0.0001
FREQUENT HIVES	3	0.0023	2	0.0022	0.4446
TIGHTNESS OF SKIN	4	0.0032	0	0.0000	0.0991
UNUSUAL HAIR LOSS	35	0.0291	8	0.0105	0.0018
TENDERNESS OF SCALP	9	0.0071	2	0.0020	0.1208

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18.25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.11

A COMPARISON BETWEEN COREGEL AND SPS OF CUMULATIVE INCIDENCE OF PATIENT REPORTED NEW POSTOPERATIVE POTENTIAL RHEUMATOLOGIC SYMPTOMS BY SYMPTOM TYPE
OVERALL PATIENTS - FDA Item 7b(1)

Symptom Type	36 Months after Implant Surgery				
	SPS (a)		CoreGel		P-value (c)
	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	Number with Symptom Type	Estimated Proportion with Symptom Type (b)	
SEVERE BRUISING WITH LITTLE OR NO INJURY	21	0.0176	7	0.0082	0.0605
COMBINED FATIGUE	166	0.1351	27	0.0304	0.0000
COMBINED PAIN	235	0.1925	60	0.0664	0.0000
COMBINED FIBROMYALGIA	111	0.0892	18	0.0190	0.0000
Any of the Above	467	0.3706	127	0.1407	0.0000
Total Patients Assessed	1680		1007		

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_11.SAS

Creation Date, Time: 09AUG04 18:25

(a) SPS does not have revision patients.

(b) Based on Kaplan-Meier estimates.

(c) p-value is from log-rank test of estimated proportion with symptom type among patients in SPS versus CoreGel.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
Symptom Type			
LOSS OF WEIGHT WITHOUT DIETING	Baseline	4/1007 (0.40)	0.8250
	1 Year	4/ 965 (0.41)	.
	2 Year	5/ 941 (0.53)	.
	3 Year	2/ 665 (0.30)	.
FATIGUE	Baseline	8/1007 (0.79)	0.0002
	1 Year	17/ 965 (1.76)	.
	2 Year	26/ 941 (2.76)	.
	3 Year	15/ 665 (2.26)	.
INSOMNIA	Baseline	24/1007 (2.38)	0.6081
	1 Year	22/ 965 (2.28)	.
	2 Year	26/ 941 (2.76)	.
	3 Year	10/ 665 (1.50)	.
WEAKNESS	Baseline	1/1007 (0.10)	0.0085
	1 Year	3/ 965 (0.31)	.
	2 Year	8/ 941 (0.85)	.
	3 Year	7/ 665 (1.05)	.
EXHAUSTION	Baseline	1/1007 (0.10)	0.0057
	1 Year	2/ 965 (0.21)	.
	2 Year	12/ 941 (1.28)	.
	3 Year	7/ 665 (1.05)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
JOINT SWELLING	Baseline	6/1007 (0.60)	0.1263
	1 Year	8/ 965 (0.83)	.
	2 Year	14/ 941 (1.49)	.
	3 Year	6/ 665 (0.90)	.
HEEL PAIN	Baseline	2/1007 (0.20)	0.0138
	1 Year	4/ 965 (0.41)	.
	2 Year	8/ 941 (0.85)	.
	3 Year	7/ 665 (1.05)	.
FREQUENT MUSCLE CRAMPS	Baseline	3/1007 (0.30)	0.0009
	1 Year	8/ 965 (0.83)	.
	2 Year	17/ 941 (1.81)	.
	3 Year	9/ 665 (1.35)	.
NUMBNESS OF FEET	Baseline	2/1007 (0.20)	0.0278
	1 Year	4/ 965 (0.41)	.
	2 Year	8/ 941 (0.85)	.
	3 Year	5/ 665 (0.75)	.
RINGING IN EARS	Baseline	10/1007 (0.99)	0.4562
	1 Year	12/ 965 (1.24)	.
	2 Year	13/ 941 (1.38)	.
	3 Year	9/ 665 (1.35)	.
PAIN/GRITINESS IN EYES	Baseline	0/1007 (0)	.
	1 Year	4/ 965 (0.41)	.

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_12.SAS

Creation Date, Time: 05NOV04 10.37

(1) p-value is from GEE model for the effect of the implant (year 1-3 visits versus baseline), adjusting for the age effect.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
PAIN/GRITTIENESS IN EYES	2 Year	4/ 941 (0.43)	.
	3 Year	2/ 665 (0.30)	.
DRYNESS OF EYES/NOSE	Baseline	14/1007 (1.39)	0.0529
	1 Year	12/ 965 (1.24)	.
	2 Year	13/ 941 (1.38)	.
	3 Year	3/ 665 (0.45)	.
PAIN ON SWALLOWING OR CHEWING	Baseline	1/1007 (0.10)	0.5140
	1 Year	1/ 965 (0.10)	.
	2 Year	3/ 941 (0.32)	.
	3 Year	1/ 665 (0.15)	.
NECK PAIN/STIFFNESS	Baseline	18/1007 (1.79)	0.6353
	1 Year	18/ 965 (1.87)	.
	2 Year	17/ 941 (1.81)	.
	3 Year	11/ 665 (1.65)	.
PAIN ON BREATHING	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	1/ 941 (0.11)	.
	3 Year	0/ 665 (0)	.
HEART MURMURS	Baseline	23/1007 (2.28)	0.0006
	1 Year	18/ 965 (1.87)	.
	2 Year	15/ 941 (1.59)	.
	3 Year	4/ 665 (0.60)	.

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_12.SAS

Creation Date, Time. 05NOV04 10:37

(1) p-value is from GEE model for the effect of the implant (year 1-3 visits versus baseline), adjusting for the age effect.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
LOSS OF APPETITE	Baseline	1/1007 (0.10)	0.2390
	1 Year	1/ 965 (0.10)	.
	2 Year	4/ 941 (0.43)	.
	3 Year	2/ 665 (0.30)	.
PERSISTENT FEVER	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
NIGHT SWEATS	Baseline	16/1007 (1.59)	0.6120
	1 Year	20/ 965 (2.07)	.
	2 Year	14/ 941 (1.49)	.
	3 Year	7/ 665 (1.05)	.
GENERALIZED ACHING	Baseline	7/1007 (0.70)	0.0309
	1 Year	8/ 965 (0.83)	.
	2 Year	19/ 941 (2.02)	.
	3 year	10/ 665 (1.50)	.
LOSS OF HEIGHT	Baseline	2/1007 (0.20)	0.1929
	1 Year	4/ 965 (0.41)	.
	2 Year	6/ 941 (0.64)	.
	3 Year	2/ 665 (0.30)	.
JOINT PAIN	Baseline	13/1007 (1.29)	0.0002
	1 Year	24/ 965 (2.49)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients	p-value (1)
		With Event n/N(%)	
JOINT PAIN	2 Year	35/ 941 (3.72)	.
	3 Year	22/ 665 (3.31)	.
FREQUENT MUSCLE PAIN	Baseline	5/1007 (0.50)	0.5295
	1 Year	10/ 965 (1.04)	.
	2 Year	10/ 941 (1.06)	.
	3 Year	2/ 665 (0.30)	.
NUMBNESS OF HANDS	Baseline	10/1007 (0.99)	0.0870
	1 Year	11/ 965 (1.14)	.
	2 Year	21/ 941 (2.23)	.
	3 Year	14/ 665 (2.11)	.
JAW PAIN	Baseline	6/1007 (0.60)	0.2939
	1 Year	6/ 965 (0.62)	.
	2 Year	3/ 941 (0.32)	.
	3 Year	2/ 665 (0.30)	.
OPEN SORES	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
REDNESS OF EYES	Baseline	3/1007 (0.30)	0.4338
	1 Year	3/ 965 (0.31)	.
	2 Year	7/ 941 (0.74)	.
	3 Year	3/ 665 (0.45)	.

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_12.SAS

Creation Date, Time: 05NOV04 10:37

(1) p-value is from GEE model for the effect of the implant (year 1-3 visits versus baseline), adjusting for the age effect.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
DRYNESS OF MOUTH	Baseline	3/1007 (0.30)	0.9685
	1 Year	2/ 965 (0.21)	.
	2 Year	4/ 941 (0.43)	.
	3 Year	3/ 665 (0.45)	.
BACK PAIN/STIFFNESS	Baseline	18/1007 (1.79)	0.8497
	1 Year	18/ 965 (1.87)	.
	2 Year	27/ 941 (2.87)	.
	3 Year	10/ 665 (1.50)	.
SEVERE CHEST PAINS	Baseline	0/1007 (0)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	1/ 665 (0.15)	.
CHRONIC COUGH	Baseline	1/1007 (0.10)	.
	1 Year	0/ 965 (0)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	2/ 665 (0.30)	.
DIFFICULTY SWALLOWING	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	1/ 665 (0.15)	.
FREQUENT,SEVERE DIARRHEA/CONSTIPATION	Baseline	8/1007 (0.79)	0.7543
	1 Year	8/ 965 (0.83)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
FREQUENT, SEVERE DIARRHEA/CONSTIPATION	2 Year	9/ 941 (0.96)	.
	3 Year	7/ 665 (1.05)	.
SEVERE RASHES	Baseline	0/1007 (0)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	0/ 665 (0)	.
SEVERE DRYNESS OF SKIN	Baseline	2/1007 (0.20)	0.0170
	1 Year	5/ 965 (0.52)	.
	2 Year	7/ 941 (0.74)	.
	3 Year	4/ 665 (0.60)	.
TENDER LUMPS/BUMPS	Baseline	1/1007 (0.10)	0.0291
	1 Year	3/ 965 (0.31)	.
	2 Year	7/ 941 (0.74)	.
	3 Year	3/ 665 (0.45)	.
EXCESSIVE SENSITIVITY TO SUN	Baseline	3/1007 (0.30)	0.9790
	1 Year	3/ 965 (0.31)	.
	2 Year	4/ 941 (0.43)	.
	3 Year	2/ 665 (0.30)	.
COLOR CHANGES ON HANDS/FEET WITH COLD EXPOSURE	Baseline	10/1007 (0.99)	0.8653
	1 Year	9/ 965 (0.93)	.
	2 Year	10/ 941 (1.06)	.
	3 Year	7/ 665 (1.05)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
FREQUENT HIVES	Baseline	1/1007 (0.10)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	0/ 665 (0)	.
TIGHTNESS OF SKIN	Baseline	1/1007 (0.10)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
UNUSUAL HAIR LOSS	Baseline	3/1007 (0.30)	0.0151
	1 Year	5/ 965 (0.52)	.
	2 Year	7/ 941 (0.74)	.
	3 Year	9/ 665 (1.35)	.
TENDERNESS OF SCALP	Baseline	1/1007 (0.10)	0.5786
	1 Year	2/ 965 (0.21)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	2/ 665 (0.30)	.
SEVERE BRUISING WITH LITTLE OR NO INJURY	Baseline	8/1007 (0.79)	0.8377
	1 Year	8/ 965 (0.83)	.
	2 Year	8/ 941 (0.85)	.
	3 Year	5/ 665 (0.75)	.
COMBINED FATIGUE	Baseline	8/1007 (0.79)	0.0002
	1 Year	17/ 965 (1.76)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients	p-value (1)
		With Event n/N(%)	
COMBINED FATIGUE	2 Year	26/ 941 (2.76)	.
	3 Year	15/ 665 (2.26)	.
COMBINED PAIN	Baseline	44/1007 (4.37)	0.2607
	1 Year	54/ 965 (5.60)	.
	2 Year	63/ 941 (6.70)	.
	3 Year	31/ 665 (4.66)	.
COMBINED FIBROMYALGIA	Baseline	5/1007 (0.50)	0.0011
	1 Year	9/ 965 (0.93)	.
	2 Year	19/ 941 (2.02)	.
	3 Year	12/ 665 (1.80)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
Symptom Category			
Skin and Appendages	Baseline	7/1007 (0.70)	0.0006
	1 Year	13/ 965 (1.35)	.
	2 Year	17/ 941 (1.81)	.
	3 Year	13/ 665 (1.95)	.
Muscle	Baseline	41/1007 (4.07)	0.7863
	1 Year	43/ 965 (4.46)	.
	2 Year	51/ 941 (5.42)	.
	3 Year	26/ 665 (3.91)	.
Joint	Baseline	16/1007 (1.59)	0.0009
	1 Year	27/ 965 (2.80)	.
	2 Year	39/ 941 (4.14)	.
	3 Year	22/ 665 (3.31)	.
CNS	Baseline	34/1007 (3.38)	0.3976
	1 Year	34/ 965 (3.52)	.
	2 Year	47/ 941 (4.99)	.
	3 Year	22/ 665 (3.31)	.
Gastrointestinal	Baseline	8/1007 (0.79)	0.4881
	1 Year	8/ 965 (0.83)	.
	2 Year	11/ 941 (1.17)	.
	3 Year	8/ 665 (1.20)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11 12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
Body as a Whole	Baseline	52/1007 (5.16)	0.5369
	1 Year	57/ 965 (5.91)	.
	2 Year	69/ 941 (7.33)	.
	3 Year	35/ 665 (5.26)	.
Metabolic and Nutritional	Baseline	4/1007 (0.40)	0.8250
	1 Year	4/ 965 (0.41)	.
	2 Year	5/ 941 (0.53)	.
	3 Year	2/ 665 (0.30)	.
Hearing and Vestibular	Baseline	10/1007 (0.99)	0.4562
	1 Year	12/ 965 (1.24)	.
	2 Year	13/ 941 (1.38)	.
	3 Year	9/ 665 (1.35)	.
Respiratory	Baseline	1/1007 (0.10)	.
	1 Year	0/ 965 (0)	.
	2 Year	3/ 941 (0.32)	.
	3 Year	2/ 665 (0.30)	.
Platelet, Bleeding, Clotting Disorder	Baseline	8/1007 (0.79)	0.8377
	1 Year	8/ 965 (0.83)	.
	2 Year	8/ 941 (0.85)	.
	3 Year	5/ 665 (0.75)	.
Cardiovascular	Baseline	23/1007 (2.28)	0.0006
	1 Year	18/ 965 (1.87)	.

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_12.SAS

Creation Date, Time: 05NOV04 10:37

(1) p-value is from GEE model for the effect of the implant (year 1-3 visits versus baseline), adjusting for the age effect.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients	p-value (1)
		With Event n/N(%)	
Cardiovascular	2 Year	15/ 941 (1.59)	.
	3 Year	4/ 665 (0.60)	.
Vision	Baseline	3/1007 (0.30)	0.0396
	1 Year	7/ 965 (0.73)	.
	2 Year	11/ 941 (1.17)	.
	3 Year	4/ 665 (0.60)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
Physical Examination Finding			
WEAK HEADLIFT	Baseline	0/1007 (0)	.
	1 Year	2/ 965 (0.21)	.
	2 Year	3/ 941 (0.32)	.
	3 Year	0/ 665 (0)	.
INABILITY TO RAISE ARMS	Baseline	1/1007 (0.10)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	1/ 941 (0.11)	.
	3 Year	0/ 665 (0)	.
INABILITY TO GET OUT OF CHAIR	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	1/ 941 (0.11)	.
	3 Year	0/ 665 (0)	.
WRIST SWELLING	Baseline	0/1007 (0)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	0/ 665 (0)	.
DIGITS SWELLING	Baseline	4/1007 (0.40)	0.0640
	1 Year	8/ 965 (0.83)	.
	2 Year	9/ 941 (0.96)	.
	3 Year	6/ 665 (0.90)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
ELBOWS SWELLING	Baseline	2/1007 (0.20)	.
	1 Year	0/ 965 (0)	.
	2 Year	3/ 941 (0.32)	.
	3 Year	0/ 665 (0)	.
KNEES SWELLING	Baseline	0/1007 (0)	.
	1 Year	2/ 965 (0.21)	.
	2 Year	4/ 941 (0.43)	.
	3 Year	4/ 665 (0.60)	.
ANKLES SWELLING	Baseline	0/1007 (0)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	4/ 941 (0.43)	.
	3 Year	2/ 665 (0.30)	.
BOUTONNIERE	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	1/ 941 (0.11)	.
	3 Year	0/ 665 (0)	.
ULNAR DRIFT	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
SWAN NECK	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.

Program Name. Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_12.SAS

Creation Date, Time: 05NOV04 10:37

(1) p-value is from GEE model for the effect of the implant (year 1-3 visits versus baseline), adjusting for the age effect.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
SWAN NECK	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
TRIGGER FINGERS	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	1/ 941 (0.11)	.
	3 Year	1/ 665 (0.15)	.
JOINT TENDERNESS	Baseline	2/1007 (0.20)	0.0039
	1 Year	5/ 965 (0.52)	.
	2 Year	15/ 941 (1.59)	.
	3 Year	10/ 665 (1.50)	.
GRIP STRENGTH AND MOTION-FINGER TO PALM CREASE	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	1/ 941 (0.11)	.
	3 Year	0/ 665 (0)	.
NECK MOTION-CHIN TO CHEST OR STERNUM	Baseline	1/1007 (0.10)	.
	1 Year	2/ 965 (0.21)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	0/ 665 (0)	.
CHEST EXPANSION	Baseline	2/1007 (0.20)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
OCCIPUT TO WALL	Baseline	0/1007 (0)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	2/ 941 (0.21)	.
	3 Year	0/ 665 (0)	.
JAW MOTION	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
BACK MOTION	Baseline	0/1007 (0)	.
	1 Year	1/ 965 (0.10)	.
	2 Year	1/ 941 (0.11)	.
	3 Year	0/ 665 (0)	.
HAIR LOSS	Baseline	3/1007 (0.30)	0.6767
	1 Year	4/ 965 (0.41)	.
	2 Year	3/ 941 (0.32)	.
	3 Year	4/ 665 (0.60)	.
SKIN TIGHTNESS	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
RAYNAUD'S PHENOMENON	Baseline	2/1007 (0.20)	0.6128
	1 Year	1/ 965 (0.10)	.

Core Gel Study of the Safety and Effectiveness of the Mentor Round Gel-Filled Mammary Prosthesis
in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Table 11.12

GEE MODEL TESTING THE EFFECT OF THE IMPLANT (YEAR 1-3 VISITS VERSUS BASELINE) ADJUSTING FOR THE AGE EFFECT - FDA Item 7b(2)

Parameter	Visit	Number of Patients With Event n/N(%)	p-value (1)
RAYNAUD'S PHENOMENON	2 Year	2/ 941 (0.21)	.
	3 Year	1/ 665 (0.15)	.
CALCINOSIS OVER TIBIA, ULNA, ELBOWS	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
SWOLLEN DIGITS	Baseline	1/1007 (0.10)	0.0305
	1 Year	2/ 965 (0.21)	.
	2 Year	6/ 941 (0.64)	.
	3 Year	3/ 665 (0.45)	.
ERYTHEMA OVER KNUCKLES	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
BLUISH HUE COLOR ON EYELIDS	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.
NON-TENDER LUMPS OR BUMPS ON ELBOWS	Baseline	0/1007 (0)	.
	1 Year	0/ 965 (0)	.
	2 Year	0/ 941 (0)	.
	3 Year	0/ 665 (0)	.

Program Name: Q:\MENTOR\COREGEL\3YEAR\TABLES\T11_12.SAS

Creation Date, Time: 05NOV04 10:37

(1) p-value is from GEE model for the effect of the implant (year 1-3 visits versus baseline), adjusting for the age effect.